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STATEMENT OF JURISDICTION 
This is an appeal from a Memorandum Decision by the Honorable Ronald E. 
Nehring of the Third Judicial District Court denying relief to shareholders who exercised 
their dissenters' rights pursuant to Utah Code Ann. § 16-10a-1302. The District Court's 
Memorandum Decision is attached hereto as Addendum A. The dissenting 
shareholders contend that they were not given "fair value" for the shares of stock they 
owned in Zinetics Medical, Inc. ("Zinetics") when the majority shareholder eliminated 
them in a "freeze-out" merger. 
This Court has jurisdiction pursuant to Utah Code Ann. § 78-2-2(3)(j). 
ISSUES PRESENTED FOR REVIEW AND STANDARD OF REVIEW 
A. Issues Presented for Review. 
1 . Did the District Court err in determining the "fair value" of the dissenting 
shareholders interest because it gave no weight to the prices at which "guideline" 
companies sold in public markets on the valuation date? This is an issue of law which 
is reviewed for correctness. See Swope v. Siegel-Robert. Inc.. 243 F.3d 486,491 (8th 
Cir. 2001) (stating that "the determination of whether a given fact or circumstance is 
relevant to fair value under [the Missouri Statute] is a question of law"); Morris v. Health 
NetofCaL Inc., 1999 UT 95, fl 5, 988 P.2d 940, 941 (holding that questions of law are 
reviewed for correctness without deference to trial court). 
2. Did the District Court err by giving no weight to the fact that the squeezed-
out minority shareholders made an offer to purchase all the majority shares of the 
company at more than twice the amount they received in the "freeze-out" merger? This 
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is an issue of law which is reviewed for correctness. See Swope. 243 F.3d at 491; 
Morris. 1999 UT 95, fl 5, 988 P.2d at 941. 
3. Did the District Court err when it failed to determine a "fair value" for the 
stock in question when faced with conflicting evidence of value? This is an issue of law 
which is reviewed for correctness. See kL 
4. Did the District Court err in determining "fair value" pursuant to Utah Code 
Ann. § 16-10a-1302 without deciding whether to apply either a "minority discount" or a 
"marketability discount?" Whether to apply a minority or marketability discount is a 
question of law reviewed for correctness. See Swope. 243 F.3d at 491; Advanced 
Communication Design. Inc. v. Follett. 615 N.W.2d 285, 289 (Minn. 2000) (stating that 
applicability of marketability discount presents question of law); Morris. 1999 UT 95, 
1J5,988P.2dat941. 
5. Was there sufficient evidence to support the District Court's ruling that 
plaintiffs were entitled to no further consideration for their shares? This challenges the 
sufficiency of the evidence and appellant must demonstrate that the clear weight of the 
evidence contradicts the District Court's conclusions. See Doelle v. Bradley. 784 P.2d 
1176, 1178 (Utah 1989) (stating that sufficiency of evidence is determined by testing 
factual finding "against the clear weight of the evidence."). 
6. Did the District Court err in determining the "fair value" of the minority 
shares because it gave no consideration to the value of identical shares held by the 
majority? See Swope. 243 F.3d at 491; Morris. 1999 UT 95, U 5, 988 P.2d at 941. 
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RELEVANT CONSTITUTIONAL PROVISIONS, STATUTES, AND RULES 
The following statute provides the basic determinative law on appeal and is 
attached hereto as Addendum B: Utah Code Ann. § 16-10a-1302. 
STATEMENT OF THE CASE 
A. Nature of the Case. 
This is an action under the Utah Dissenters' Rights Act to determine the fair 
value of the dissenting shareholders' interest in Zinetics. On or about January 23, 
1998, Zinetics' Board of Directors approved an Agreement and Plan of Reorganization 
("Reorganization Plan"), the terms of which provided for the merger of Zinetics with 
Medtronic GB, Inc., a wholly-owned subsidiary of Medtronic, Inc. ("Medtronic"). See 
Addendum A at 1-2. At that time, Medtronic owned approximately 80% of Zinetics' 
stock. fcL at 2. Under the Reorganization Plan, certain shares of Zinetics' stock would 
be canceled and paid at $.0428 per share. Pursuant to that Reorganization Plan, on 
February 13, 1998, majority shareholder Medtronic squeezed out the dissenting 
shareholders. ]d. The dissenting shareholders rejected the $.0428 per share offer and 
chose instead to pursue a remedy in the District Court, id. at 1-2. 
On May 29, 1998, the minority shareholders filed a Petition for Determination of 
Fair Value Under Utah Code Ann. § 16-10a-1330. After a four-day bench trial the 
Honorable Ronald Nehring determined not to award the minority shareholders any 
additional compensation. See Addendum A at 16. The minority shareholders' appeal 
follows. 
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STATEMENT OF THE FACTS 
The minority shareholders respectfully submit that the evidence adduced at trial 
established the following ultimate facts: 
1. In April 1983, Dr. H. Mack Brown incorporated Zinetics under the name 
Nuestro Research. See Addendum A at 2. The Hogle family provided the company an 
initial $500,000 of capital investment. See Testimony of Hogle, R. 1043 at 440. 
Between 1987 and 1991, the Kearns-Tribune Company ("Kearns-Tribune"), became 
both a significant investor in Zinetics and its majority shareholder. See Testimony of 
Gallivan, R. 1040 at 26-32. By 1991, Kearns-Tribune held over 8 1 % of Zinetics' stock. 
Testimony of Hogle, R. 1043 at 444. 
2. The minority shareholders invested in Zinetics during the period from 
1984 to 1998. See Testimony of Mack Brown, R. 1042 at 369; Don Hale, R. 1042 at 
375; Garth Read, R. 1040 at 24. The vast majority of the minority have held their 
shares for more than 10 years. idL These shareholders paid from $0.10 to $0.17 per 
share. kL Over the years, the minority shareholders have invested a great deal of 
time, money, and energy in Zinetics with the belief that it had value and, if allowed to 
grow, to its potential would provide them with a healthy return on their investment. kL 
3. In 1991, Zinetics had successfully researched, developed, and brought to 
market a much needed catheter and was rounding the comer to financial success, 
despite the fact that it had required a small infusion of capital to fend off insolvency, 
partially resulting from the embezzlement activities of a former corporate officer. See 
Testimony of Hogle, R. 1043 at 458; see also Addendum A at 3. 
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4. Up to and including the valuation date, Zinetics was a company that had 
been experiencing robust financial performances that continued to increase the value of 
its shares. For instance, 
(a) from August 31,1993 to January 2,1998, the total assets increased at a 
compounded annual growth rate of 30.5% from $502,000 to $1.6 million (see Ex. TT, R. 
at 1403, attached hereto as Addendum C at 3); 
(b) total current assets increased from $413,000 as of August 31,1993 to 
$1.413 million as of January 2,1998. Cash and current equivalents represented 88.1% 
of total assets as of January 2,1998 (Addendum C at 3); 
(c) total liabilities, conversely, decreased from $200,000 as of August 31, 
1993 to $115,000 at January 2,1998, at which time total liabilities represented only 
7.2% of total assets (id,); 
(d) total stockholder's equity increased from $302,000 to $1.489 million 
during the period from August 31,1993 to January 2,1998 (Id.); 
(e) from fiscal 1993 through the last twelve-month period ("LTM"), total 
revenues increased at a compounded annual growth rate of 19.3%, from $1,213 million 
to $2,612 million (Addendum C at 4); 
(f) gross profit margins ranged from a low of 53.2% for the year ended 
August 31,1993 to a high of 62.7% for the year ended August 31,1997. The five-year 
average gross profit margin was 59.0% (ia\); 
(g) operating income for the LTM period was $455,000 versus $184,000 for 
fiscal year 1993, providing a compounded annual growth rate of 23.1% (id,); and 
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(h) Zinetics' profitability ratios indicate very strong returns on investments. 
The company's returns on average equity on an average total invested capital have 
observed period averages of 37.6% and 36.8%, respectively (Addendum C at 3-4). 
5. In 1991, Synectics purchased 81% of Zinetics from Kearns-Tribune in 
what was characterized, colloquially, as a "steal." Addendum A at 3. Despite the fact 
that Zinetics had reached a turning point in its operations and had begun to 
successfully market its products to others - including Synectics - Synectics was able to 
acquire its control position for around $255,000 or $0.006242 a share. kL 
6. Each of the minority shareholders who owned an interest in Zinetics at 
that time testified at trial if they had been extended the opportunity to purchase those 
shares at the same price or to make a counteroffer - which they were not - they most 
certainly would have done so. See Testimony of Hogle, R. 1043 at 446. As the 
shareholders testified, they had invested millions of dollars for their approximately 20% 
interest in the company. It defies reason to suggest that they would not pay $255,000 
for the remaining 80%. \j± 
7. After 1991, while an affiliate of Synectics, Zinetics "enjoyed consistent 
revenue growth and profitability." Addendum A at 3. 
8. At least since the acquisition of Synectics by Medtronic, the minority 
shareholders had been perceived as a thorn in the side of Medtronic. See Testimony of 
Robert Paulson, R. 1041 at 40-41. The strategies of the two factions were at 
loggerheads. \± at 41. Medtronic wished to operate Zinetics as a captive Original 
Equipment Manufacturing ("OEM") facility that would manufacture and transfer products 
to affiliates as Medtronic deemed most efficient. JdL In contrast, the minority 
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shareholders wished Zinetics to pursue an independent strategy that would maximize 
opportunity and future profits at the Zinetics level. See Testimony of Johnson, R. 1040 
at 67. 
9. Predictably, Medtronic's solution was to take action designed to dispose 
of the minority shareholders. Medtronic continually offered to buy out the minorities1 
interest at prices far below fair value. See R. 1403 at Exs. N, DD; see also Testimony 
of Johnson, Murray, and Paulson. In response, the minority counterproposed to 
purchase the majority on the same basis. See Testimony of Johnson, R. 1040 at 88. 
The majority rejected those counteroffers, jd. at 91. 
10. The minority also sought to increase the amount of information publically 
available about Zinetics in order to stimulate more active trading and a more robust 
market. See Testimony of Hogle, R. 1043 at 452; see ajso R. 1403 at Exs. O, P. The 
majority refused to assist, direct, or encourage the dissemination of information to the 
public and would only provide information as required by securities authorities. See Id. 
at 456; see also R. 1403 at Exs. F, O, P, FF. Thus, the majority effectively stifled the 
ability of the minority to capitalize on the increased value of Zinetics by selling shares in 
the market, id. at 458-63. 
11. The minority shareholders offered evidence supporting the fact that 
Zinetics' present and future revenues and profits, and thus the value of its shares, 
would have been significantly greater had Medtronic/Synectics not purposefully 
suppressed the value of Zinetics to its own benefit. See Testimony of Hogle, R. 1043 at 
469. Synectics controlled the Zinetics1 Board of Directors (see Testimony of Hogle, R. 
1043 at 447-49) and through that control engaged in self-dealing tactics such as forcing 
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Zinetics to sell its products at low prices and then marking the products up 70% so that 
the high profit margin hit Synectics/Medtronic's bottom line (kL at 449) rather than that 
of Zinetics and by requiring Zinetics to pay Synectics/Medtronic further and excessive 
charges for the distribution of their own products to Synectics/Medtronic and its 
customers. See id. 
12. Moreover, despite the minority's continuing requests that they do so, 
Synectics/Medtronic refused to allow Zinetics to raise additional capital, to acquire new 
technology, to authorize the research and development of new products that Zinetics 
management wished to pursue, or to allow Zinetics a free hand generally in 
management decisions. See Testimony of Hogle, R. 1043 at 451-52; see also R. 1403 
at Exs. E and N. 
13. In particular, Medtronic/Synectics prevented Zinetics from investing in or 
engaging in research and development or bringing to market the solid state catheter, 
the glass catheter, the 24M catheter or the 24ME catheter, and prevented Zinetics from 
developing flourescent technology. The evidence shows that all such research 
development, and marketing would have increased Zinetics' bottom line, future 
prospects, and value.1 See Testimony of Hogle, R. 1043 at 458. Developing those 
products was feasible and would have contributed significant income to Zinetics. 
Further evidence of this fact is that despite Medtronic's protestations that the product 
lines were not feasible or would not be profitable, it developed and began to market at 
1
 Among the reasons Medtronic's expert, Mr. Norman, gave for down 
valuing Zinetics was that the company was essentially stagnant without significant 
research and development. Thus, Medtronic uses its own unfair tactics in oppressively 
managing Zinetics to bolster its case for a low value. 
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least some of those products soon after it squeezed out the minority shareholders. See 
Testimony of Davis, R. 1042 at 387. 
14. Medtronic's representatives contended that Davis* plans for new product 
lines were unrealistic and unattainable. See Testimony of R. Allen, R. 1044 at 656-57. 
15. Medtronic persuaded the District Court that it had not artificially 
suppressed transfer pricing, stifled a public market in Zinetics1 stock, or prevented 
Zinetics from developing new product lines. The District Court concluded that the 
minority shareholders could not prove a nexis between the alleged suppression and the 
corporate merger that triggered the dissenters' rights. As pointed out by the District 
Court, the only evidence offered by the minority shareholders to establish a "nexus" 
between the suppression and the squeeze-out merger was "that Zinetics post-merger 
revenues experienced an unusual upswing." Addendum A at 9. 
16. As the District Court noted, the minority shareholders' "suppression 
theory" is animated by the assumption that a rational corporation which owns a 
controlling interest in an affiliate corporation will engage, as a matter of course, in 
practices designed to minimize the apparent value of the affiliate as part of a strategy to 
squeeze-out disgruntled minority shareholders at the lowest possible cost. Addendum 
A at 8. 
17. "Although this assumption may be firmly rooted in realities of the rough 
and tumble world of market capitalism, it cannot alone influence an appraisal of fair 
value." See Addendum A at 9. 
18. Despite repeated requests by the minority and Zinetics' management, 
Medtronic/Synectics refused to assist in the development of a public market for Zinetics' 
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stock. See Testimony of Hogle, R. 1043 at 462; see also R. 1403 at Exs. E and P. As 
William Murray testified, Medtronic/Synectics refused to provide any more information 
to the public or to the minority shareholders than was legally required. See Testimony 
of Murray, R. 1041 at 152-53; Hogle, R. 1043 at 457; see also R. 1403 at Exs. I, O, P. 
Medtronic/Synectics admitted that if a buyer purchases a publicly traded company then 
that buyer would have to pay market price. See Testimony of Paulson, R. 1041 at 38. 
By refusing to assist in or encourage public trading of Zinetics' stock, 
Medtronic/Synectics effectively ensured that it could set the value of Zinetics' stock at 
any arbitrarily chosen point and insist that the minority shareholders were getting a fair 
price for their stock at the time of the squeeze-out merger. Furthermore, 
Medtronic/Synectics could claim that the actual trading prices have no probative value 
because Zinetics traded in a thin market. 
19. When Medtronic acquired Synectics in 1996, negotiations to buy out the 
minority shareholders or for the minority shareholders to buy out Medtronic/Synectics 
took on a new fervor. James Hogle, Ronald Johnson, and Patrick Hogle represented 
the majority of the minority shareholders in those negotiations. Robert Paulson and 
William Murray were the primary negotiators for Medtronic/Synectics. 
20. On July 30, 1996, the minority shareholders, represented by James 
Hogle, wrote to Medtronic to discuss various options for Medtronic to achieve its 
apparent goal of buying out the minority shareholders and stated the minority's 
preferences in that regard. See R. 1403 at Ex. E. By that letter, the minority offered to 
sell for cash and/or exchange for Medtronic shares their Zinetics' shares at $0.20 per 
share. The minority indicated that their second preference would be to actively grow 
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Zinetics as a Medtronic-owned subsidiary by (1) providing Zinetics' management with 
working capital; and (2) completing a secondary public offering of Zinetics1 shares to 
gain capital for the company to advance and expand marketing on existing and new 
products, develop new products, expand its research and development division, and to 
expand its manufacturing facilities and capabilities. kJL 
21. In March 1997, Medtronic/Synectics offered to purchase the minority 
interests for $400,000 in cash, or $0.0175 per share. See R. 1403 at Ex. 42. The 
minority rejected this offer and, in turn, offered to acquire Medtronic/Synectics1 interest 
in Zinetics at the same price per share. \jL Medtronic then offered to acquire the 
minority interest at $850,000, or $0,036 per share. See Testimony of Johnson, R. 1040 
at 55. The minority also rejected this offer due to their belief that it did not reflect the 
company's true value and offered to buy Medtronic/Synectics1 shares at that same 
price. See R. 1403 at Ex. N. 
22. In October 1997, the minority offered to purchase 80% of 
Medtronic/Synectics' interest (approximately 60% of Zinetics' stock) for $3,875,000 paid 
over time. See Testimony of R. Johnson, R. 1040 at 57; see also R. 1403 at Ex. S. 
That offer included an exclusive supply and distribution agreement for Medtronic, thus 
ensuring that Medtronic/Synectics would continue to receive Zinetics products on the 
same extremely favorable terms as it had during the time Medtronic/Synectics owned a 
majority interest. 
23. Ultimately and unbeknownst to the minority, Medtronic/Synectics decided 
that it preferred to forcefully acquire the minority shares of Zinetics rather than sell its 
interest in Zinetics to the minority. Without telling the minority shareholders of its 
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decision to squeeze them out Medtronic/Synectics continued to behave as if they were 
negotiating a deal by which the minority would buy out its interest in Zinetics. 
24. The minority shareholders, primarily through Ronald Johnson, Patrick 
Hogle and Steve Davis, worked hard to offer deal terms to which Medtronic/Synectics 
would agree. The deal hinged on the Supply and Distribution Agreement. See R. 1403 
at Exs. T, U, W, X, Z, AA, BB, and CC. 
25. On January 7,1998, William Murray and Robert Paulson informed Steve 
Davis and Ronald Johnson that they wanted to schedule a meeting in Salt Lake City on 
January 23, 1988 - allegedly to finalize the terms of the deal. See Testimony of Hogle, 
R. 1043 at 466-67; Johnson, R. 1040 at 75; see also R. 1403 at Ex. CC. 
26. On January 20, 1998, unbeknownst to the minority shareholders, 
Medtronic created an Agreement and Plan of Reorganization. See R. 1403 at Ex. DD. 
As a result of the proposed merger, Medtronic would own 100% of Zinetics and all 
minority shareholders would receive $0.04528 per share. \j± 
27. Believing that they still had a deal, the majority of the minority 
shareholders met on January 21, 1998 to discuss the deal's particulars. At or near the 
time of the meeting, the minority was blindsided by notice of Medtronic/Synectics1 
merger proposal. See Testimony of Johnson, R. 1040 at 76-77, 87; Hogle, R. 1043 at 
467; see also R. 1403 at Exs. FF, GG, HH. 
28. Disbelieving that all their hard work had been for nothing, Mr. Johnson 
and Mr. Hogle, through their attorney, scheduled a meeting with Messrs. Paulson and 
Murray seeking an explanation. See Testimony of Johnson, R. 1040 at 80-81; Hogle, 
R. 1043 at 166-67. At that meeting, the minority made a last ditch effort to buy out 
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Medtronic/Synectics at $0.10 per share plus a non-exclusive, uninterrupted Supply and 
Distribution Agreement, id. Messrs. Paulson and Murray rejected the offer because 
they were unable to advance without a two-year exclusive dealing arrangement. See 
j d ; Testimony of Paulson, R. 1041 at 88. 
29. On January 23, 1998, Zinetics' Special Board Meeting was held. The 
Board voted to adopt the Plan of Reorganization without recommendation and sent the 
proposal to Zinetics' shareholders for approval. See R. 1403 at Ex. DD. 
30. During the days prior to shareholders meeting, the minority continued to 
pursue their offer to Medtronic/Synectics to buy out Medtronic at $0.10 per share with a 
non-exclusive supply and distribution agreement. See Testimony of Johnson, R. 1040 
at 83-85; Paulson, R. 1041 at 88; Exs. HH and MM. To prevent the minority from taking 
other action, Medtronic/ Synectics pretended to consider the minority's $0.10 per share 
offer. See R. 1403 at Exs. J J and MM. 
31. Medtronic unreasonably refused to allow the minority the necessary time 
to structure financing to complete the deal. See R. 1403 at Exs. J J, MM, and NN; see 
also Testimony of Hogle, R. 1043 at 467-68; Johnson, R. 1040 at 87-88. Medtronic 
now attempts to lead the Court to believe that it rejected the offer because it did not 
believe the minority could find the financing and dismisses the offer as not bona fide. 
The evidence clearly shows, however, that given time, the minority shareholders could 
have found the financing needed to complete the deal. See Testimony of Johnson, R. 
1040 at 88. 
32. Had the minority shareholders been able to purchase the company, 
Zinetics would have been a successful stand-alone company. Testimony of Reilly, R. 
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1043 at 520-21; Johnson, R. 1040 at 90. Davis testified that he had connections within 
the industry to sell Zinetics' products directly to end users and had connections with 
other distributors of medical products who would distribute Zinetics' products. In 
addition, Zinetics had a guaranteed income from Medtronic/Synectics, who testified that 
even if they chose to pursue an alternative supplier, they would be required to purchase 
Zinetics* products for at least two years after they initiated that pursuit. See Testimony 
of Johnson, R. 1040 at 83. Medtronic/Synectics' refusal to pay market prices for the 
catheters it purchased from Zinetics is further evidence of Medtronic's self-dealing to 
the detriment of the minority shareholders. See R. 1403 at Exs. HH, JJ, MM, and NN.) 
33. In sum, Medtronic/Synectics rejected $0.10 per share for their shares of 
Zinetics' stock just prior to the forced merger - more than twice what it paid to the 
minority shareholders in the squeeze-out merger. See Testimony of Johnson, R. 1040 
at 80-81; see also R. 1403 at Exs. HH, JJ, MM, and NN. Every time 
Medtronic/Synectics made an offer to purchase the minority shares, the minority offered 
to buy the majority at the same price. See Testimony of Johnson, R. 1040 at 80-85. 
Each and every time, Medtronic/Synectics rejected the offer. JdL 
34. The squeeze-out merger was consummated on February 13,1998, during 
a Special Shareholders' Meeting which many minority shareholders attended and 
voiced their dissent. See Testimony of Hogle, R. 1043 at 468. The minority 
shareholders voted against the merger. Thereafter, each of the minority shareholders 
complied with the procedural requirements of the Utah Dissenters' Rights Act to perfect 
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their right to receive the fair value of their shares. Pursuant to the Statute, Zinetics filed 
a Petition for a Determination of Fair Value on May 29,1998 (the "Petition").2 
35. On or about the valuation date, Medtronic's stock traded at more than 50 
times earnings and at the time of trial traded as high as 80 to 90 times earnings. kL; 
see also Addendum C. 
36. At trial, Appellants offered the expert testimony of Robert Reilly. Mr. 
Reilly, co-author of Valuing a Business: the Analysis and Appraisal of Closely Held 
Companies, submitted an appraisal report (see generally Addendum C) and testified at 
length. See generally Testimony of Reilly. Mr. Reilly performed a market valuation, 
based on actual share prices of the most similar companies. As explained in more 
detail, the method is the only method that uses actual stock market prices on the 
valuation date to value Zinetics' shares. The District Court rejected this methodology 
on the basis (1) it has "not been recognized as a valuation tool by our court" 
(Addendum A at 11), and (2) the method would yield "values which would fluctuate 
inexplicably over time in a manner unrelated to the financial performance of the 
companies." Addendum A at 14. 
37. Appellees offered the expert testimony of Merrill Norman to value the 
shares in question. Similar to Mr. Reilly, Mr. Norman performed a "market valuation" of 
the shares based on stock prices of companies he termed "comparables." The 
companies that he used were primarily the largest medical companies in the world and 
thus not suitable. See R. 1403 at Ex. SS at 8-9. Mr. Norman purported to resolve that 
2
 See Utah Code Ann. § 16-10a-1328. 
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problem by adjusting the results of several factors, id. at 9. The court rejected Mr. 
Norman's market valuation because of the size dissimilarity and adjustment technique. 
Addendum A at 15. 
38. Mr. Norman also performed income analyses, each of which produced 
values well below the price offered in the squeeze-out merger. In fact, without certain 
adjustments, his income indicators would have produced values of nearly "0." 
39. Appellees also adduced the testimony of Mr. Paulsen of Medtronic who 
testified that the price offered was fair although he did not perform a valuation analysis. 
40. In the end, the Court rejected all expert testimony regarding the fair value 
of the dissenters' share and summarily concluded that the fair value of those shares fell 
below the amount that Medtronic offered during the squeeze-out merger. Addendum A 
at 16. 
SUMMARY OF THE ARGUMENT 
The District Court erred in its interpretation of Oakridqe Energy. Inc. v. Clifton. 
937 P.2d 130 (Utah 1997) and, as a result, did not award the dissenting shareholders 
the "fair value" of their shares. Unlike the view taken by the District Court, Oakridqe 
takes an expansive view of the factors a court should consider in making a 
determination of fair value. In this case, the District Court failed to consider important 
evidence that impacted the value of Zinetics' shares. Consequently, the Court 
erroneously concluded that the minority shareholders had been adequately 
compensated. 
First, the District Court committed a fundamental error by failing to give proper 
consideration to the "market valuation" of the shares in question. Mr. Reilly based his 
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market valuation on the median of an array of similar companies. The median ratios of 
those guideline companies' share prices to revenue was applied to the subject 
company's revenues to give a market value for the shares on the valuation date. The 
District Court rejected that market valuation method based on the flawed assumption 
that the courts have not accepted the method. The Oakridqe court, however, found 
such methods to be of substantial probative value. Evidence based on fluctuating 
periods of time, i.e., dates other than the day of valuation, is of little merit. 
The District Court further erroneously concluded that Mr. Reilly's market 
valuation method "has not been recognized as a valuation tool by our courts." 
Addendum A at 11 (citing Oakridge). The Court was wrong. The methodology has 
often been used with approval by this Court in property tax cases. See Salt Lake City 
S. R.R. Co. v. Utah State Tax Comm'n. 1999 UT 90, fflf 1-13, 987 P.2d 594, 595-98; 
Mallinckrodt v. Salt Lake County. 1999 UT 66, U 9, 983 P.2d 566, 569. 
Another of the court's flawed criticisms of the "market valuation" method is that 
the methodology would reflect fluctuating values at different points of time. However, 
the Dissenters' Rights Act requires a valuation method to be discretely and rigorously 
applied at a certain point in time. The market valuation method selects the most 
comparable companies as of the valuation date. Those companies would not 
necessarily be the most comparable at some other point in time. The fact remains that 
share prices on the markets fluctuate wildly and often for no apparent reason. By 
statute, the valuation must be as of a date certain. See Utah Code Ann. § 16-10a-
1301(4). In rejecting this evidence, the Court committed legal error and misinterpreted 
both the statute and Oakridqe. This error alone requires reversal. 
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The District Court also erred in failing to give any weight to the fact that the 
minority shareholders attempted to purchase the majority shares for $0.10 a share just 
before the squeeze-out merger. The District Court's opinion does not even address 
that issue. This is an equitable proceeding seeking "fair value" - surely that evidence is 
entitled to some consideration. 
Similarly, the District Court did not address the value of this company to its 
parent. The parent, Medtronic, Inc., is a holding company with more than a hundred 
subsidiaries. It trades at roughly 50 to 80 times the price-earnings ratio. See 
Testimony of Murray, Paulsen. Based on both Zinetics' earnings as well as the price-
earnings ratio of Medtronic, Zinetics had a value to Medtronic of $0.20 to $0.32/share in 
market capitalization. Thus, it is not surprising Medtronic would not sell its shares to the 
minority shareholders at $0.10 - twice more than it forced the majority to accept. 
Finally, the District Court failed to determine the fair value of the shares. It 
rejected Mr. Norman's market valuation and held his income valuation would have to be 
adjusted by adjusting revenues and capitalization rates as Mr. Reilly had opined. 
However, if one uses Reilly's revenue and capitalization rates, one derives Reilly's 
value, not Norman's. Thus, the District Court was left with no evidence to support its 
conclusion that the minority is entitled to no compensation. 
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ARGUMENT 
I. THE COURT ERRED IN GIVING NO WEIGHT TO MARKET VALUATION. 
A. The Court Rejected the Most Probative Testimony Offered to 
Determine the Fair Value of the Zinetics' Shares. 
The District Court needed to determine the fair market value of Zinetics1 shares 
on the valuation date, February 12, 1998. Mr. Reilly presented extensive analysis of 
what similar companies traded for in the market on that very date. The District Court 
rejected this testimony apparently on two grounds. First, the Court found that such 
evidence and methodology "has not been recognized as a valuation tool by our courts." 
Addendum A at 11. Contrary to the District Court, the market valuation approach is a 
methodology often used and presented to Utah courts, particularly in questions of 
property tax valuation where the "stock and debt" value of a company not traded on 
exchange is estimated. See, e.g. Salt Lake City S. R.R. Co. v. Utah State Tax Comm'n. 
1999 UT 90, mi 1-13, 987 P.2d 594, 595-98; Mallinckrodt v. Salt Lake County. 1999 UT 
66, U 9, 983 P.2d 566, 569 
Second, the Court rejected Reilly's methodology because the market value-to-
revenue ratio used would yield values "which fluctuated inexplicitly over time in a 
manner unrelated to the fundamental financial performance of the companies." 
Addendum A at 14. Again, this is a misapplication of law. 
The statute requires a valuation to be made on or as of a specific date. See 
Utah Code Ann. § 16-10a-1301(4). Prices of shares have always fluctuated wildly in 
the stock market. The ratios demonstrated by the market - whether they be price-to-
earnings, price-to-revenue, book-to-revenue, also fluctuate wildly. Statute requires the 
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court to determine the value of those shares on a particular day, not over any period of 
time. The fact that the value of shares and their underlying market ratios may have 
varied significantly over time is irrelevant and to be expected. 
Mr. Reilly observed the market relationships that existed as of the date in 
question. He used the share prices for the guideline companies on that date, and he 
used the ratios observed by comparing those share prices with the most current 
revenue information available. When one seeks to determine the fair value of shares, 
the most probative evidence should be the price at which shares of the most similar 
companies trade on that very date. Mr. Reilly employed a technique consistent with the 
methodology set forth in his book, Valuing a Business: The Analysis and Appraisal of 
Closely Held Companies. 
A market analysis of the value of the shares of a company, and more particularly 
the guideline company method, is used when the actual market price of a security is not 
known but its present and historical financial performance is. This case presents a 
prime example because the shares of Zinetics were so thinly traded that no expert 
relied on the actual price of trades in calculating a value. See Section EJ, infra. The 
guideline company method is of long standing and well respected. See Chapter 10 of 
Mr. Reilly's book, Valuing a Business, at 203-38. One relies on this method when, as is 
often the case of a business, there is no single business that is "comparable" to the 
company whose shares are to be valued. As Mr. Reilly described in his testimony, 
Guideline companies are similar to the subject company, they typically are 
in the same or similar industry but don't make exactly the same product, 
they are similar - they are subject to the same risk and return 
characteristics from an investment perspective. They have the same sort 
of customers, they have the same sort of suppliers, they are similar to the 
F:\USERS\CMW\Hogle\Plead\open.brief.wpd 2 0 
subject company in many ways, but would not be considered direct and 
comparable.... If you don't have a directly comparable company, you're 
probably going to look for six or eight or ten or more guideline companies, 
companies when you put them together as a portfolio have 
characteristics, again from investment risk and rate of return perspective, 
that are similar to the subject company, though no one particular company 
may look exactly like the subject company. 
Tr. at 503-04. 
B. This Court Should Adopt Mr. Reilly's Market Analysis Because it 
Most Accurately Reflects the Value of Zinetics. 
This Court should adopt Mr. Reilly's market analysis because it most accurately 
reflects the fair value of the dissenting shareholders' interest in Zinetics. Mr. Reilly's 
market analysis is the only methodology which values Zinetics* shares with reference to 
market data of comparable companies without engaging in untested mathematical 
contortions. In fact Mr. Reilly's appraisal, when considered in light of the testimony of 
other witnesses regarding self dealing, mismanagement, and suppression, undervalues 
Zinetics. 
Mr. Reilly began his market analysis by designating the criteria that would 
determine the companies to serve as guidelines for the value of Zinetics. Guideline 
companies are those that are similar to Zinetics both with respect to business activities 
and financial status. See Addendum C at 8. Importantly, Medtronic expert, Mr. 
Norman, testified that he agreed with the selection criteria chosen by Mr. Reilly. Mr. 
Norman just wasn't happy with the result of the search. 
Mr. Reilly's market approach began with 11,400 publicly traded companies. Mr. 
Reilly began to narrow his search for comparable companies by identifying the most 
appropriate Standard Industrial Classification (SIC) code. He chose SIC code 3841 -
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surgical and medical instruments and apparatus, the principal SIC code for Zinetics. 
See Addendum C at Appendix C. Mr. Reilly further refined his array of guideline 
companies by selecting companies that manufactured catheters, the same medical 
device manufactured by Zinetics. From that point, Mr. Reilly further scrutinized the 
guideline companies and selected those that were similar to Zinetics in terms of size 
and revenues and limited his search to those companies actually producing a product 
and generating revenues. The eleven guideline companies appearing in Appendix C to 
his report are the only companies from the 11,400 publicly traded companies examined 
by Mr. Reilly that meet those criteria. Mr. Reilly added no companies to the list, he 
deleted no companies from the list.3 As Mr. Reilly testified, his eleven companies are 
"the best companies on the planet Earth" to use as guidelines for the value of Zinetics. 
Once the selection criteria produced a list of companies, Mr. Reilly derived a 
value for Zinetics by calculating a pricing multiple for the guideline companies based on 
the ratio of the market value of invested capital to revenues and then applying that 
multiple to Zinetics. See Addendum C at 8. This calculation was based on the actual 
historical revenues of Zinetics compared to the guideline companies without any 
adjustment for mismanagement or self-dealing by Medtronic, without consideration for 
new products Zinetics was prevented from marketing and without quantifying the impact 
of Medtronic's refusal to disseminate information about Zinetics to the public. The 
result is a value of $28,168 million. 
3
 Appendix C to Mr. Reilly's report fully details the guideline companies 
selected by Mr. Reilly's criteria. See Addendum C at Appendix C. 
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After conceding that he agreed with Mr. Reilly's selection criteria, Mr. Norman 
attempted to rebut Mr. Reilly's market analysis by claiming that the market cap to 
revenue ratio was an inappropriate indicator of value. The market cap to revenue ratio 
is simple a comparison of two numbers provided in a company's financial report. No 
better or worse a ratio then any other. Mr. Norman tried to argue that the market cap to 
revenue ratio failed to have predictive value because in his mind investors valued 
revenues irrationally. Mr. Norman attempts to look into the minds of investors and tell 
this Court why investors act the way they do. The only real way to determine what 
investors value is to examine their conduct in the market place. Mr. Reilly does just 
that. He does not pretend to read investors minds, only to evaluate the results of their 
decisions. Based on an examination of the market and objective criteria, Mr. Reilly 
arrived at a value for Zinetics. 
In sum, Mr. Reilly's market approach simply derives a value for Zinetics by 
utilizing selection criteria approved by both appraisers and applying market data to the 
actual historical performance of Zinetics. As such Mr. Reilly's market approach is 
clearly the most accurate approximation of the fair value of Zinetics' shares. 
C. Contrary to the District Court's Opinion, Mr. Reilly Did Not Use 
Actual Market Prices for Zinetics' Shares in His Valuation. 
The District Court apparently misunderstood Mr. Reilly's discussion of the prices 
at which Zinetics' stock had actually traded in the period prior to the merger. The 
District Court devoted approximately two pages (pp. 10-11) of its Memorandum 
Decision to rejecting evidence of actual shares trade prices as unreliable. This is odd 
because nobody, including Mr. Reilly, contended that actual share prices were reliable. 
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The District Court quotes Mr. Reilly as stating that these trading prices were 
"noteworthy" and that it "reasonably reflected the marketable minority interest per share 
market value of Zinetics1 common stock." Addendum A at 10. 
Mr. Reilly, both in his written report and in his testimony, was unequivocal that he 
placed no reliance whatsoever on those share prices in his determination and opinion 
of value. The following is his testimony at trial with respect to actual trades in Zinetics 
Medical. 
Q. Let me direct you to page 6 of your report, Exhibit TT. You have 
portrayed on this page, Mr. Reilly, some pricing and volume activity for 
Zinetics Medical during the period of October 13th, I guess, to February 
A. Yes I went back and looked at the last four months of trading activity prior 
to the valuation date. 
Q. As far as you could determine, was this the only trading activity that 
occurred, at least that was reported? 
A. During this period, yes. 
Q. You are aware, are you not, that one of - two of these transactions, 
325,000 shares approximately, really only represented Mr. Johnson 
transferring some of his shares from one - from his ownership to a family 
trust or something of that nature. 
A. Well, I'm aware of that only because you told me that, so I will accept that. 
Q. Did you make any use of the fact that these trades had occurred in the 
calculations of value that you made? 
A. No, in mv valuation I didn't use this data at all. Zinetics, though, is a non-
publicly reporting OTC company, so it is relevant to see what type of 
trading volume, what type of trading prices exist, so that's why I did 
perform this analysis and I did find this (inaudible) due to lack of volume of 
these trades I didn't rely upon it at all. 
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It doesn't affect my conclusion at all, but it does indicate that some shares 
of stock did trade in the range of eight cents a share to about 17 cents a 
share in the four months prior to the valuation date. 
Tr. at 540-41. 
In his report (see Addendum C), Mr. Reilly stated, as regards the actual trading 
prices of Zinetics' stock: 
While this indication of value is certainly noteworthy, we have not 
(emphasis added) specifically included the market described valuation 
indication in our valuation synthesis and conclusion. 
Thus, the discussion by the Court is misdirected and confused because of the 
fact that Mr. Reilly never used the data discussed as a valuation tool in rendering his 
opinion. It was simply information that he observed and found consistent with his 
valuation. It would have been rather strange if Mr. Reilly had not even bothered to look 
to see if there had been any trades - including the volume and prices of any trades. It 
would have also been strange had he rested his opinion of value on this data. Such 
reliance would have been inconsistent with the Oakridge decision and inconsistent with 
valuation technique. However, this entire discussion by the Court is irrelevant and 
suggests that the Court was not focused on Mr. Reilly's testimony with the necessary 
rigor. 
II. THE DISTRICT COURT ERRED IN GIVING NO WEIGHT TO OTHER 
PROBATIVE VALUATION EVIDENCE. 
A. The Court Erred in Giving No Weight Whatsoever to the Minority 
Shareholders' Attempt to Negotiate a Purchase of the Majority 
Shares. 
As summarized at pages 11 through 15, supra, the minority shareholders, led by 
Mr. Johnson and Mr. Hogle, persistently attempted to purchase the majority block of 
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shares by offering the same price at prices at which the majority offered to buy out the 
minority. In connection with these offers, the minority offered supply agreements to 
Medtronic to ensure the latter would have the supply of catheters for its sales and 
distribution efforts. During much of the course of these negotiations, the majority block 
owned indirectly by Medtronic demanded an exclusive supply contract. Thus, the 
majority wanted to have its cake and eat it too. In the event the majority sold its block 
of shares of Zinetics, it wanted to ensure that it would be the only entity with the right to 
purchase its products for some period of time. Although an onerous condition, the 
minority shareholders attempted to structure a contract that would give exclusivity for 
some period of time. 
Eventually, the minority shareholders offered $0.10 per share for each of the 
majority held shares and was willing to enter into a non-exclusive supply contract that 
would set the prices at which the products would be transferred for some period of time. 
This last offer came when the Medtronic personnel - who had indicated they were 
coming to Salt Lake to negotiate a final version of a supply contract - announced that 
they were there to institute a freeze-out merger. The freeze-out merger took the 
minority shareholders completely by surprise. Nonetheless, the minority quickly reacted 
by making the $0.10 per share offer, which was rejected the majority because the 
minority needed some modest period of time to put the financing together. 
Appellants submit that the Court erred by failing to give any recognition in its 
opinion to this evidence. The District Court simply ignored all that evidence. At its core, 
the Dissenters' Right Statute is an equitable remedy. That statute should provide "fair 
value" to the minority. As this Court stated in Oakridae. a court should consider "all 
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relevant evidence" when determining the fair value. The fact that the minority was 
always willing to match any per share offer that the majority made, and eventually 
doubled the last offer should be given some weight in determining fair value. Even 
though substantial testimony at trial was devoted to chronicling these events, the 
District Court did not even give it passing reference in its Memorandum Decision. 
Appellants respectfully suggest that in the case of a freeze-out merger, such as this 
case, the Court should have given due consideration to the minority to purchase the 
majority block and the prices offered. 
B. The District Court Erred in Not Giving Any Weight to the Value of 
Zinetics' Shares to its Parent Company, Medtronic. 
Given the equitable nature of this proceeding, the District Court should have 
considered Zinetics1 value to the parent company, Medtronic. Zinetics and its products 
were uniquely valuable to Medtronic. At the intermediate, Synectics, level, Medtronic 
made a 70% mark-up over the transfer price it paid Zinetics for Zinetics1 products. 
Moreover, because Medtronic owned more than 80% of the shares of Zinetics, it was 
able to consolidate its financials. Because of this, the market capitalization of 
Medtronic reflected the contribution to earnings of Zinetics. In fact, as has been noted, 
the last 12 months historic earnings of Zinetics had a market capitalization value to 
Medtronic of from 20 to 32 cents per share of Zinetics' stock, based upon a price-to-
earnings ratio at the Medtronic level which varied from 50 to 85 per share. Medtronic 
employees admitted that they refused to allow Synectics to manufacture and distribute 
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additional products until such time as the minority shareholders were eliminated.4 They 
did not want the added value to accrue to Zinetics when they were minority 
shareholders. After the freeze-out merger was consummated and the minority 
shareholders eliminated, Zinetics was allowed to increase its manufacturing and 
distribution of products and experienced growth in earnings, up to a level of $600,000 a 
month - far greater than historic Zinetics' earnings. 
Appellants submit that the District Court erred by not giving any weight or 
consideration to this evidence. 
III. THE APPLICATION OF A MINORITY DISCOUNT OR A MARKETABILITY 
DISCOUNT IS INAPPLICABLE IN CALCULATING THE FAIR VALUE OF THE 
DISSENTERS' SHARES. 
Because the District Court fails to properly articulate a basis for its conclusion 
that the dissenting shareholders received fair value for their shares, one cannot 
determine whether the Court applied a minority or marketability discount. The 
dissenting shareholders argued in their pre-trial brief that any such discounts are wholly 
inappropriate. The Court did not issue a ruling on that issue, nor did the Court discuss 
those discounts in its Memorandum Decision. See generally Addendum A. Thus, the 
dissenting shareholders respectfully request that, on remand, this Court direct the 
District Court to determine fair value excluding any minority or marketability discounts. 
The Utah Dissenters' Rights Act provides that dissenting shareholders are 
entitled to receive "fair value" for their shares in a company that has effected a merger. 
4
 In its Memorandum Decision, the District Court recognized that Zinetics' 
earnings took a dramatic upswing immediately after Medtronic rid itself of the minority 
shareholders. See Addendum A at 9. 
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Utah Code Ann. § 16-1 Oa-1302(1 )(a) ("A shareholder, whether or not entitled to vote, is 
entitled to dissent from, and obtain payment of the fair value of shares held by him in 
the event o f . . . consummation of a plan of merger..."). The Act defines fair value as 
"the value of the [dissenters1] shares immediately before the effectuation of the 
corporate action to which the dissenter objects, excluding any appreciation or 
depreciation in anticipation of the corporate action." \j± § 16-10a-1301 (4). Although the 
statutory definition of fair value does not indicate whether a minority discount or a 
marketability discount is proper, a majority of courts have held that fair value is not to be 
equated with fair market value. That concept incorporates the application of a minority 
or marketability discount. Walter S. Cheesman Realty Co. v. Moore. 770 P.2d 1308, 
1311 (Colo. Ct. App. 1988) ("We agree that the term 'fair value' as used in the 
dissenters' rights statute imports a broader approach to valuation than does the term 
'fair market value."1). 
A minority discount is an adjustment that an appraiser makes to the value of 
shares based on the theory that the minority shares are not worth the same as the 
majority holdings due to a lack of voting power or control over the corporation. In 
contrast, a marketability discount allows an appraiser to adjust for a lack of liquidity in 
the stock itself based on the theory that there is a limited supply of potential purchasers 
of the stock. See Hood, et al., Valuation of Closely Held Business Interest 65 UMKC L. 
Rev. 399,438 (1997). Both of those adjustments are inapplicable in this case. 
The majority of courts to address this issue have refused the application of a 
minority discount and held that a minority discount is improper in assessing the "fair 
value" of a dissenter's shares: 
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[T]he majority of courts addressing the issue of minority discounts has 
held that discounts should not be taken when determining fair value of 
minority shares sold to another shareholder or to the corporation. These 
courts clarify that discounts at the shareholder level are inherently unfair 
to the minority shareholder who did not pick the timing of the transaction 
and is not in the position of a willing seller. Thus, these courts hold that a 
dissenting shareholder's position should be the equivalent of what it would 
have been had the fundamental change not occurred. Moreover, they 
reason that valuing the shares at less than their proportionate share of the 
corporation's fair value produces a transfer of wealth from the minority 
shareholder to the shareholders in control. 
Hansen v. 75 Ranch Co.. 957 P.2d 32,41 (Mont. 1998) (internal citations omitted); see 
also. MT Props.. Inc. v. CMC Real Estate Corp.. 481 N.W.2d 383, 388 (Minn. Ct. App. 
1992) (M[B]ecause the legislature has enacted the statute with the evident aim to protect 
the dissenting shareholder, we must prohibit application of minority discounts when 
determining 'fair value' in statutory dissenter's rights cases in Minnesota. This result is 
also in accord with the approach of the majority of states which have addressed this 
issue.") (footnote omitted).5 
Likewise, a majority of courts shun imposing a marketability discount on 
squeezed-out shareholders. Arnaud v. Stockqrowers State Bank of Ashland. 992 P.2d 
216, 218 (Kan. 1999) ("Cases and commentators suggest that the majority of states 
6
 No Utah case has addressed this issue; however, this Court, in Oakridge. 
937 P.2d 130 (Utah 1997), held that sole reliance on market trading price of a stock to 
determine "fair value" of a dissenter's shares was error. kL at 133. The Oakridge Court 
adopted an expansive view of the term "fair value." Moreover, in reaching this holding, 
the Court cited to authority from Iowa and Maine. Both of these states have held that a 
minority discount is improper, jd; see Woodward v. Quiqlev. 133 N.W.2d 38,44 (Iowa 
1965) ("[T]he statute is designed to protect the minority from the very considerations 
which result in discounted value . . . . By statute the minority is guaranteed the Year 
value of its stock."); In re Valuation of Common Stock of McLoon Oil Co.. 565 A.2d 997, 
1003 (Me. 1989) ("In our view application of [minority or nonmarketability] discounts 
would run directly counter to our appraisal statute's purpose of protecting dissenting 
shareholders"). 
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have not applied minority and marketability discounts when determining the fair value of 
stock.H); see also In re Valuation of Common Stock of McLoon Oil Co.. 565 A.2d 997, 
1002 (Me. 1989) (stating application of a marketability discount would run counter to the 
purpose of protecting dissenting shareholders); Cavalier Oil Corp. v. Harnett. 564 A.2d 
1137, 1145 (Del. 1989) (same); Securitv State Bank v. Zieaeldorf. 554 N.W.2d 884, 890 
(Iowa 1996) (concluding that marketability discounts undermine legislative intent to 
protect minority shareholders); Rigel Corp. v. Cutchall. 511 N.W.2d 519, 525-26 (Neb. 
1994) (holding both minority and marketability discounts inappropriate in an action for 
appraisal of dissenting shareholders' interests); Lawson Mardon Wheaton. Inc. v. 
Smith. 734 A.2d 738, 752 (concluding marketability discounts should not be applied); 
Charland v. Country View Golf Club. Inc.. 588 A.2d 609, 611 (R.I. 1991) (holding 
marketability discounts should not be applied when a corporation purchases stock from 
its minority shareholders). 
The remedial purpose of the Dissenters' Rights Act would be undermined if this 
Court were to permit minority or marketability discount. The Montana Supreme Court 
recognized this principle in finding illegal the application of a minority discount: 
Moreover, we recognize that the dissenters' rights provisions of the Model 
Business Corporation Act, as adopted by the Montana legislature, were 
fashioned as a legislative remedy for minority shareholders who find their 
interests threatened by significant corporate changes. The dissenters' 
rights provisions protect the minority shareholders by allowing them to 
obtain payment of fair value for their shares. Based on this policy, many 
courts realize that applying discounts when valuing the shares of a 
dissenting shareholder destroys the legislative intent to protect the 
minority shareholder's right to dissent. 
Hansen. 957 P.2d at 41-42 (internal citations omitted). "More important, to fail to 
accord to a minority shareholder the full proportionate value of his shares imposes a 
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penalty for lack of control, and unfairly enriches the majority shareholders who may 
reap a windfall from the appraisal process by cashing out a dissenting shareholder, a 
clearly undesirable result." Cavalier. 564 A.2d at 1145. 
This Court has embraced this same rationale relied upon by the Montana 
Supreme Court, as well as other courts, in disallowing a minority discount. See 
Oakridqe. 937 P.2d at 133 n.2 ("Statutes like ours were typically enacted to protect 
minority shareholders, replacing the common law rule that votes on corporate sales and 
mergers must be unanimous.") (citation omitted). The stated public policy of protecting 
dissenting shareholders requires that the Court find the minority and marketability 
discounts inapplicable. 
This Court should conclude that it is improper under Utah law to impose or to 
accept a valuation employing a minority discount or a marketability discount on the 
shares of dissenting shareholders. In this case, the dissenting shareholders were 
forced, in the face of corporate merger and reorganization, to sell their interests back to 
the company. The majority legal view is that minority and marketability discounts are 
inconsistent with the basic policies underlying Dissenters' Rights Statutes and should 
not be applied. Mr. Norman, expert for Medtronic, incorporated a marketability discount 
in the fair value determination of the shares held by the dissenters. The District Court 
remained silent as to whether it applied such a discount. Given those facts, and the 
wealth of legal authority to the contrary, this Court should conclude that the application 
of a minority or marketability discount is inappropriate under the Utah Dissenters' Rights 
Act and should not impose either a minority or marketability discount on the dissenting 
shareholders. 
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IV. THERE IS NO EVIDENCE TO SUPPORT THE DISTRICT COURT'S 
CONCLUSION THAT APPELLANTS ARE ENTITLED TO NO ADDITIONAL 
COMPENSATION FOR THE SHARE OF ZINETICS THEY WERE FORCED TO 
SURRENDER. 
Under Utah Code Ann. § 16-10a-1302, the frozen-out minority shareholders 
were entitled to the "fair value" of the shares they were forced to relinquish. Thus, the 
one inescapable issue the Court had before it was to determine the fair value of a share 
of Zinetics on the valuation date. The District Court never answered that question. 
More importantly, the District Court had no support in the record for its conclusion that 
whatever the fair value was it was not greater than the price set by the Appellees. 
The value of a share of stock cannot be determined by anecdotal evidence. 
Thus, opinions about the "fairness" of the price set or the "reasonableness" of a price is 
of little, if any, probative value unless it is supported by rigorous methodology. In 
support of the portion that the fair value of the shares was less than the freeze-out 
merger price, Appellees offered only one witness, Merrill Norman, who purported to 
determine value. Mr. Norman valued the shares on a market valuation methodology 
and on using an income methodology. If there is to be support in the record for the 
District Court's conclusion, it must reside in Mr. Norman's testimony and report. The 
District Court, however, rejected Mr. Norman's opinions. As to his market based 
methodology, the Court totally rejected that approach. Addendum A at 11-13. With 
respect to Mr. Norman's income methodology, the District Court agreed that it was 
deficient in many respects, as Mr. Reilly had testified. Addendum A at 15-16. 
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Inexplicably the Court then concluded, without support, that jf the criticisms that 
Mr. Reilly made were applied to Mr. Norman's analysis, the result would be less than 
the freeze-out merger price stating as follows: 
When the numbers proposed by respondent [Appellants] for revenue, 
discount rate and capitalization rate are used to recalculation [sic] Mr. 
Norman's investment valuations, the results do not exceed the $0.04528 
per share offered by Medtronic for the respondent's common stock. 
Addendum A at 16. 
Nowhere did the District Court provide any support for its contention that the fair 
value for Zinetics' shares is below $0.04528. In fact, it cannot. Fundamental to Mr. 
Reilly's criticism of Mr. Norman's income analysis was that he looked at a company that 
had experienced consistent, robust growth at an average of 19.3% and projected a 
decrease in income of 15% for his first, base year projection. Because that first year 
was the basis for all future years, this unjustified decision cascaded through all future 
years. Mr. Norman then compounded the problem by using future growth rates (after 
the initial decrease) of 10% instead of the historic 19.3%. The District Court agreed 
that this was improper. 
If one recalculates the income, or investment, values with the revenues and 
capitalization rates proposed by Mr. Reilly, one would of necessity conclude with 
income, or investments, values similar to those found by Mr. Reilly, which are far more 
than $0.04528 per share. 
The result of all this is that the District Court has no valuation testimony 
supporting the conclusion. 
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CONCLUSION 
The fundamental error made by the District Court was the rejection, as a matter 
of law, of the most probative evidence offered - the market valuation of Zinetics1 share 
based upon an analysis of the most similar companies trading publically on the 
valuation date. Because of this, the District Court found itself at sea. Because the 
District Court rejected all the evidence that could have supported its conclusion that no 
further compensation need be paid to Appellants, the decision should be reversed. 
Appellants respectfully suggest that this Court remand the matter for further 
consideration and order the District Court to: 
1. Appoint a special master with expertise in valuation; 
2. Give weight to the market valuation method using guideline companies; 
3. Give proper consideration to the Appellants' $0.10 cents/share offer to the 
majority prior to the merger and the value to the majority of the Zinetics' shares; and 
4. Not apply a minority or marketability discount. 
DATED this7 ^day of June, 2001. 
BENDINGER, CROCKETT, 
PETERSON & CASEY 
170 South Main Street, Suite 400 
Salt Lake City, Utah 84101 
By rfaju^i, tf- -ffibtikfyD 
Attorneys for Appellants '& 
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Tab A 
IN THE DISTRICT COURT OF THE THIRD JUDICIAL DISTRICT 
IN AND FOR SALT LAKE COUNTY, STATE OF UTAH 
ZINETICS MEDICAL, INC., : MEMORANDUM DECISION 
a Utah corporation, 
Petitioner, CASE NO. 980905416 
VS. 
AYYOOB ABBASZADEH, et al., 
Respondents. 
This action brought to determine the fair value of Zinetics, 
Inc.. pursuant to the Utah Revised Business Corporation Act (the 
"Act"), Utah Code Ann., Section 16-10a-101, et seq. was tried 
before me on November 30, 1999 through December 3, 1999. The 
parties made closing arguments on February 28, 2000. William Z. 
Pentelovitch, Esq, and Alain M. Baudry, Esq. represented the 
petitioner. Respondents appeared through their counsel, Robert A. 
Peterson, Esq., Rebecca S. Parr, Esq., and Karen L. Martinez, Esq. 
Zinetics Medical, Inc. is a corporation engaged in the 
manufacture of catheters used in the diagnosis of gastrointestinal 
disease. 
On February 13, 1998, a special meeting of Zinetics' 
shareholders was held in Salt Lake City. At that meeting, an 
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Agreement and Plan of Reorganization was approved authorizing the 
merger of Zmetics with Medtronic G.B., Inc., a wholly-owned 
subsidiary of Medtronic, Inc. Under the terms of the Agreement and 
Plan of Reorganization the shares of Zmetics common stock were 
converted into the right to receive cash of 4.528 cents per share. 
The respondents are dissenting shareholders who exercised their 
right under the Act to seek a Court determination of the fair value 
for their shares of Zmetics common stock as of February 12, 1998. 
My evaluation of the fair value of the Zmetics common stock 
requires that I determine organizational and performance 
characteristics most likely to maximize value1 and that I adopt and 
apply an appraisal methodology which generates a value with the 
most legitimate claim to validity. 
I. Findings relating to Zinetics' structure and operations 
Zmetics was incorporated in 1983 for the purpose of bringing 
to the marketplace disposable gastrointestinal catheters developed 
primarily by Dr. Harold Mack Brown, a Professor of Physiology at 
the University of Utah. Although revenue figures for Zmetics for 
'This exercise was directed primarily to assess whether Zinetics should be valued as a 
subsidiary of Medtronics, a stand-alone company, or an entity with hybrid features. This analysis 
required an evaluation of the probability that the performance projection presented for each proposed 
corporate structure would come to pass if implemented by the company. It was not, therefore, a 
task identical to a traditional ''highest and best use" analysis. 
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the years 1983-1991 were not made part of the record, it is 
undisputed that Zmetics sustained net losses for each of these 
years. Dr. Brown attributed the losses to a distribution network 
which he characterized as "thin." Zmetics was also victimized 
during this period by an embezzlement loss of approximately 
$400,000 perpetrated by a company manager. The Kearns-Tribune 
Corporation was a ma]or investor m Zmetics. Minutes of the 
meetings of the Board of Directors of the Kearns-Tribune 
Corporation between mid-1987 and November 1991 recount Zmetics' 
ongoing struggle to achieve profitability and chronic need for 
cash. 
In November 1991, Synectics Medical, Inc. ("Synectics") gained 
a controlling interest in Zmetics, acquiring 81.7% of the 
outstanding shares. Synectics was a wholly-owned subsidiary of 
Medtronic, Inc. At the time Synectics acquired its controlling 
interest in Zmetics, the Kearns-Tribune Corporation owned 
105,241,550 shares of Zmetics common stock. Synectics bought tne 
shares owned by the Kearns-Tribune Corporation for $255,000, or 
approximately 2.4 cents per share. Synectics retained control over 
Zmetics until Medtronics' acquisition of the company in February, 
1998 While an affiliate of Synectics, Zmetics enjoyed consistent 
revenue growth and profitability. 
Several issues are central to determining the characteristics 
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of Zmetics for purposes of assessing its intrinsic value. First, 
it is necessary to determine whether Zmetics should oe valued as 
an affiliate of Synectics or as a stand-alone company. Next, it is 
necessary to determine whether Synectics and Medtronic exploited 
their control over Zmetics by suppressing product development and 
the intrinsic value of the company until such time as it could 
effect a "squeeze out" of the minority shareholders.2 
I find that Zmetics' intrinsic value would most likely be 
maximized as an affiliate of Synectics. I further find that 
insufficient evidence exists to support a conclusion that decisions 
made by the Zmetics Board of Directors while controlled by 
Synectics were improperly made with an eye toward repressing the 
value of Zmetics until the minority shareholders could be 
"squeezed out." 
Of greatest relevance in reaching my finding that Zmetics 
enjoys greater intrinsic value as a Synectics affiliate than as a 
stand-alone company, is the historical performance of the company. 
2I have considered and reject petitioner's assertion that corporate misconduct issues, 
litigated and dismissed with prejudice in an earlier shareholder den\ative action, are therefore 
barred by the doctrine oi res judicata. I find that the allegations of corporate misconduct have 
relevance in this action to the central issue of fair value which clearly survives a claim preclusion 
challenge. Although the issue preclusion branch oi res judicata appears to put respondent's 
allegations at risk, I interpret the language of the Stipulation and Order dismissing the derivative 
action to express an intention that the corporate suppression claims be preserved for presentation in 
this action. 
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It is undisputed that Zmetics did not become profitable until 
becoming an affiliate of Synectics. This fact underscores the 
importance of a reliable market and effective distribution network 
to the performance of the company. Although it is not unusual for 
startup companies to struggle, sometimes for years, while nurturing 
an effective and efficient product distribution network, Zmetics 
demonstrated little or no market development or distribution 
progress until after its affiliation with Synectics. One can easily 
harvest from the record ample evidence - the minutes of the Kearns-
Tribune Board of Directors is but one example - that Zmetic's 
product development was well advanced in the pre-Synectics years 
and that it was the absence of an effective marketing and 
distribution network that created the sole barrier to Zmetic's 
profitability. 
It is likewise clear that Zmetics was largely dependent on 
Synectics both as a customer for its products and as its primary 
product distribution vehicle to the catheter market. As a stand-
alone company, Zmetics would no longer be the beneficiary of 
Synectics as either a customer or a distributor. Moreover, 
Zmetics would be at a competitive disadvantage as a stand-alone 
due to its limited product line. Unlike its major competitors as 
a stand-alone company, Sandhill and Synectics, Zmetics could not 
offer a full range of gastroenterological diagnostic products and 
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would be unable to exploit the appeal of an integrated system to 
health care providers. Synectics/Medtronics acknowledged that 
maintaining an uninterrupted flow of catheter products was a matter 
of hign priority to the company. It also conceded that it would 
take oetween one and two years for Synectics/Medtronics to develop 
its own catheter manufacturing facilities to a level which would 
make them capable of fully replacing the catheters formerly 
supplied by Zinetics.3 Zinetics would clearly own competitive 
leverage over Synectics and Medtronics during this window and could 
be expected to command considerable price increases over the 
previous transfer pricing structure. I am not convinced, however, 
that any additional revenues which Zinetics might have expected 
from sales to Synectics/Medtronics during this period would have 
been sufficient to finance the development of an effective 
distribution network and research and development initiatives. 
I reject, as unsupported by the evidence, the minority 
shareholders' contention that Zinetics could have prospered as a 
stand-alone company but for Synectics' efforts to frustrate the 
Respondents challenge the assertion that Synectics/Medtronics would compete with Zinetics 
based on the "Hotelian Theory" which, according to respondents' expert, Mr Robert Reilly, would 
render the move "economically irrational " Left unexplained is how or whether the Hotelian Theory 
would account for the decision of Sandhill, Zinetics former customer, to enter into direct 
competition with Zinetics 
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development of products which would have positioned the company to 
compete effectively against Sandhill and Synectics. The 
dissenters' assertion of product suppression focused on the glass 
catheter and fluorescent catheter technology. Mr. Steve Davis, 
Zmetics1 President, was a proponent of developing a glass catheter 
to augment Zmetics' product line. His glass catheter initiative 
was opposed by Synectics' two representatives on Zmetics three 
member Board of Directors, Mr. Hans Neisz and Mr. William Murray. 
Mr. Murray, who believed that Zmetics generally took an overly 
optimistic view of the potential for the growth of the diagnostic 
catheter market, noted that Mr. Davis never responded to his 
request that a business plan be prepared for the glass catheter. 
For his part, Mr. Neisz articulated rational business reasons for 
opposing development of the glass catheter, including concerns 
about the potential market for the product, as well as unease over 
the product's safety. Skepticism about the glass catheter was 
shared by Dr. Milan Heath, Zmetics' Director of Research, who had 
no affiliation with Synectics. 
Mr. Davis also promoted the development of a catheter which 
utilized flourescent technology. Mr. Neisz shared with Mr. Davis 
the view that flourescent technology held promise, but concluded 
that Zmetics did not have the resources to pursue development and 
manufacture of a flourescent catheter. 
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I am similarly unpersuaded that Synectics/Medtronics blocked 
efforts to create a public market for Zmetics shares, motivated by 
a desire to repress share value in anticipation of purchasing the 
minority interests. To the extent that efforts to create a market 
for Zmetics' shares were rebuffed by the Synectics/Medtronics 
appointees to the Zmetics board of directors, the rationale for 
doing so - to avoid the additional filing requirements associated 
with public market-making - is legitimate, even when considered in 
the light of other alleged acts of value suppression. 
Finally, the claim that the value of Zmetics share was 
artificially suppressed by the transfer pricing structure governing 
sales between Zmetics and Synectics is unsupported by the 
evidence. I credit Mr. Ross Allen's testimony that the prices paid 
by Synectics for Zmetics' catheters was in line with prices paid 
by non-affiliated customers for the same product. En short, the 
evidence supports the conclusion that the prices paid by Synectics 
for Zmetics' products were market driven. 
Respondents' suppression theory is animated by the assumption 
that a rational corporation which owns a controlling interest in an 
affiliate corporation will engage, as a matter of course, in 
practices designed to minimize the apparent value of the affiliate 
as part of a strategy to "squeeze out" disgruntled minority 
shareholders at the lowest possible cost. Although this assumption 
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may be firmly rooted in realities of the rough and tumble world of 
market capitalism, it cannot alone influence an appraisal of fair 
value. Respondents must prove a nexus between the 
Synectics/Medtronics' alleged oppressive activities and the 
corporate action triggering the dissenters' rights such that one 
can be found to have been "in anticipation" of the other. 
Respondents could present in aid of its nexus claim only the 
general observation that Zinetics post-merger revenues experienced 
an unusual upswing.4 This is not enough. 
In summary, I find that Zinetics should be valued as a 
subsidiary of Synectics/Medtronics without regard to value 
enhancements related to respondents claim of product suppression.5 
II. Methodology for determining fair value 
Having determined that a fair value determination of Zinetics' 
shares as of February 12, 1998 must be based on an evaluation of 
4Petitioner objects to my consideration of any post-merger events. Because my reliance on 
post-merger evidence is, at most, incidental, it is unnecessary to discuss this issue at length. I note 
only that as a general matter it is seldom appropriate to categorically exclude evidence as irrelevant. 
Here, and in fair value cases generally, post-merger events may be useful in the pursuit of truth (See 
U.R.E. 102) by, among other things, corroborating or impeaching evidence relating to pre-merger 
conduct or events. 
5My findings necessarily mean that I am affording little weight to Mr. Davis's projections 
to the extent that they include predictions of revenues derived from new product development. 
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Zmetics as an affiliate of Synectics, I next turn to the task of 
selecting and employing the appropriate valuation methodology. A 
fair value assessment of a corporation requires consideration of 
market value, investment value, and asset value. Oakridge Energy, 
Inc. v. Clifton, 937 P.2d 130 (Utah 1997) . Asset value is 
generally viewed as the least reliable of these factors of value 
determination. Id. Neither petitioners nor respondents presented 
evidence of asset value, and I will not consider it as part of my 
fair value analysis. 
Respondents urge me to place considerable weight on the market 
value of Zmetics' shares. This is appropriate, they urge, because 
a valuation based on the actual price paid for the shares yields a 
result free of the multifarious assumptions and projections which 
compromise the reliability of the various investment value 
techniques. Although respondents concede that Zmetics' shares were 
thinly traded on the over-the-counter market, they nevertheless 
stand by their conclusion that trading activity for the four months 
prior to February 12, 1998 indicates a fair value of 17.2 cents per 
share. Dissenters' expert, Mr. Reilly, characterized this trading 
history as "noteworthy" and that it "reasonably reflected the 
marketable, minority interest per share market value of tne 
Zmetics common stock." I disagree. Trades in Zmetics common 
stock occurred very infrequently--too infrequently in my view to 
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provide reliable data bearing on Zmetics' fair value. The trades 
which occurred from October 13, 1997 through January 8, 1998, are 
also unreliable because they involved sales made by dissenting 
shareholders who were then involved in negotiations with Synectics 
over the future of the company. One trade of a block of 325,000 
shares was a sale by Mr. Ronald Johnson to his own IRA. The last 
two trades occurring in February, 1998, took place after the merger 
and minority share price had been announced. These market 
environments are clearly not conducive to producing share values 
which reflect accurately the intrinsic worth of the company. To 
the contrary, they are trades which do not reveal the existence of 
a free and open market for Zmetics shares, but rather an 
appreciation in value in anticipation of corporate action and 
therefore ineligible for fair value consideration. 
Both parties concentrated their valuation efforts on two 
valuation methodologies: the market approach to value, and the 
investment approach to value. The market approach attempts to 
derive value by comparing Zmetics to the values of companies with 
which it shares certain common characteristics. It is a method 
which has not been recognized as a valuation tool by our courts. 
See, Oakridge Energy v. Clifton, supra. I do not, however, 
interpret Oakridae Energy to restrict a fair value analysis to the 
three methodologies approved in the decision. While eligible for 
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consideration, the market approach analyses presented by both 
petitioner's expert, Mr. Merrill Norman, and by respondent's 
expert, Mr. Reilly, are both so fundamentally flawed that I decline 
to rely on them. 
Neither expert could discover even one company which could 
reasonably be characterized as "comparable" to Zinetics. 
Tellingly, a 1996 appraisal of Zinetics, performed by a Salt Lake 
City accounting firm at the request of Medtronics, concluded that 
no public companies could be found suitable for comparison with 
Zinetics. Mr. Norman attempted to cope with the paucity of 
comparable companies by selecting at random companies which 
manufacture medical products irrespective of size or other economic 
characteristics and applying certain adjustments to valuation to 
accommodate dissimilarities.6 For example, Mr. Norman concluded 
that a 42.76% downwards adjustment in value was appropriate to make 
allowance for size differences between his set of comparable 
companies and Zinetics. An adjustment of this magnitude seriously 
6Both experts assumed that the appropriate subset of companies from which candidates for 
comparison to Zinetics should be selected was defined by product line, i.e. medical products or 
catheters. This decision made it more difficult to locate companies with other similarities to 
Zinetics, e.g. sales, net revenues, etc. More reliable market valuation data may have emerged had 
candidates for comparison been selected based on considerations of economic performance across 
product lines with adjustments made, as necessary, to accommodate differences in markets for 
dissimilar products. 
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impairs the validity of the comparison. As noted by Mr. Reilly, 
authoritative sources in the field of valuation view adjustments in 
excess of 50% with considerable suspicion. And for good reason. 
The necessity of a 50% adjustment suggests that the subjects of the 
comparison are more different than alike. Errors which could be 
expected to infect the comparison through the application of 
adjustments geared to account for such substantial dissimilarities 
would render any meaningful comparison futile. The adjustments 
used by Mr. Norman in his analysis highlight the difficulties 
inherent in reaching a fair value determination based on market 
comparisons. Mr. Norman acknowledges these shortcomings by 
assigning a lesser weight to the market valuation method than his 
investment method. I have even less confidence in its utility than 
Mr. Norman and extend only modest regard for his market approach 
findings. 
Mr. Reilly1s market approach analysis is also seriously 
flawed, but for different reasons. Mr. Reilly's market approach 
does not use adjustments to mitigate the effects of structural and 
performance differences between comparable companies and Zmetics. 
His methodology led to the selection of "guideline" publicly traded 
companies with primary focus on one company, Rochester Medical, 
which he offers up as the most suitable candidate for comparison to 
Zmetics for valuation purposes. Mr. Reilly valued his guideline 
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companies using the ratio of the market value of invested capital 
(MVIC) to revenues. Petitioners assailed Mr. Reilly's use of the 
MVIC/revenues pricing multiple technique by demonstrating that it 
yielded values which fluctuated inexplicably over time in a manner 
unrelated to the fundamental financial performance of the 
companies. Petitioner's critique is persuasive. Because I do not 
believe that Mr. Reilly's methodology produces values of Zmetics 
over time which would correspond to historical trends in the 
company's performance measured by revenue or net income, I conclude 
that Mr. Reilly's market approach, like Mr. Norman's, should be 
substantially disregarded as unreliable. 
Our supreme court has adopted the widely accepted view that 
investment value is the most important of the three recognized 
valuation methods. Qakridae Energy, supra. The Oakridge Energy 
court defined investment value as an estimate of a corporation's 
earning capacity based on an analysis of capitalized earnings. 
Both Mr. Norman and Mr. Reilly performed valuations based on the 
investment value model, although both styled their analyses 
"Income Approach to Value". In addition to a capitalized earnings 
analysis, Mr. Norman performed valuations based on discounted cash 
flows, capitalized cash flows, and discounted earnings. Mr. Reilly 
limited his investment analysis to discounted cash flow. 
I find that the most reliable valuation method is an 
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investment valuation of Zinetics as a subsidiary of 
Synectics/Medtronics and otherwise subject to my finding set out in 
Part I of this decision. Mr. Norman's investment valuation 
analysis closely fits this criteria, particularly the data, 
projections and analyses contained in Schedules F, G, H, I, J, K, 
L and N to Mr. Norman's report. The values of Zinetics generated 
by Mr. Norman's investment approach range from $2,584,265 based on 
discounted cash flows to a low of $2,170,219 based on discounted 
earnings. 
Respondents take issue with Mr. Norman's investment valuation 
on several fronts. First, they note that Mr. Norman inexplicably 
reduced Zinetics' anticipated earnings 1998 from actual 1997 
earnings.7 This is a matter of some consequence since 1998 is the 
baseline year for projections of future performance and errors in 
the baseline year will compound over time. 
Respondents further note that Mr. Norman's projections take 
into account only expected unit price increases and fail to account 
for inflation. 
Respondents also challenge Mr. Norman's 
discount/capitalization rate calculation by asserting that it is 
improper to increase investor rate of return expectations using 
7Zinetics 1998 actual revenues closely matched Mr. Norman's projections. 
ZINETICS V. ABBASZADEH PAGE 16 MEMORANDUM DECISION 
both a small company and micro cap company adjustment. 
Each of these criticisms of Mr. Norman's investment valuation 
has a measure of merit. When the numbers proposed by respondents 
for revenue, discount rate and capitalization rate are used to 
recalculation Mr. Norman's investment valuations, the results do 
not exceed the $.04528 per share offered by Medtronics for the 
respondents' common stock. 
Based on the foregoing, I conclude that the fair value of 
Zinetics' common stock is less than $.04528 per share and that, 
accordingly, respondents have received fair^Y^lue for their stock. 
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16 JOa-1302- Right to dissent. 
(1) A shareholder, whether or not entitled to vote, is entitled to dissent from, 
and obtain payment of the fair value of shares held by him in the event of, am 
of the following corporate actions: 
(a) consummation of a plan of merger to which the corporation is a 
party if: 
(i) shareholder approval is required for the merger by Section 
16-10a-l]03 or the articles of incorporation; or 
(ii) the corporation is a subsidiary that is merged with its parent 
under Section 16-10a-1104; 
(b) consummation of a plan of share exchange to wThich the corporation 
is a party as the corporation whose shares will be acquired: 
(c) consummation o\ a sale, lease, exchange, or other disposition of all, 
or substantially all. of the property of the corporation for which a 
shareholder vote is required under Subsection 16-10a-1202(l), but not 
including a sale for cash pursuant to a plan by which all or substantially 
all of the net proceeds of the sale will be distributed to the shareholders 
within one year after the date of sale; and 
(d) consummation of a sale, lease, exchange, or other disposition of all, 
or substantially all, of the property of an entity controlled by the 
corporation if the shareholders of the corporation were entitled to vote 
upon the consent of the corporation to the disposition pursuant to 
Subsection 16-10a-1202(2i. 
(2) A shareholder is entitled to dissent and obtain payment of the fair value 
of his shares in the event of any other corporate action to the extent the articles 
of incorporation, bylaws, or a resolution of the board of directors so provides. 
(3) Notwithstanding the other provisions of this part, except to the extent 
otherwise provided in the articles of incorporation, bylaws, or a resolution of 
390 
REVISED BUSINESS CORPORATION ACT 16-10a-1302 
the board of directors, and subject to the limitations set forth in Subsection (4,. 
.•! shareholder is not entitled to dissent and obtain payment under Subsection 
< 1 » of the fair value of the shares oi any class or series of shares which eithei 
were listed on a national securities exchange registered under the federal 
Securities Exchange Act of 1934. as amended, or on the National Market 
System of the National Association of Securities Dealers Automated Quotation 
System, or were held oi record by more than 2.000 shareholders, at the time of: 
(a) the record date fixed under Section 16-10a-707 to determine the 
shareholders entitled to receive notice of the shareholders' meeting at 
which the corporate action is submitted to a vote: 
(b) the record date fixed under Section ]6-10a-704 to determine share-
holders entitled to sign writings consenting to the proposed corporate 
action; or 
(c) the effective date of the corporate action if the corporate action is-
authorized other than by a vote of shareholders. 
(4) The limitation set forth in Subsection (3) does not apply if the share-
holder will receive for his shares, pursuant to the corporate action, anything 
except: 
(a) shares of the corporation surviving the consummation of the plan of 
merger or share exchange; 
(b) shares of a corporation which at the effective date of the plan of 
merger or share exchange either will be listed on a national securities 
exchange registered under the federal Securities Exchange Act of 1934, as 
amended, or on the National Market System of the National Association of 
Securities Dealers Automated Quotation System, or will be held of record 
by more than 2.000 shareholders; 
(c) cash in lieu of fractional shares; or 
(d) any combination of the shares described in Subsection (4), or cash in 
lieu of fractional shares. 
(5) A shareholder entitled to dissent and obtain payment for his shares 
under this part may not challenge the corporate action creating the entitle-
ment unless the action is unlawful or fraudulent with respect to him or to the 
corporation. 
NOTES TO DECISIONS 
History: C. 1953, 36-]0a-1302, enacted by 
L. 1992, ch. 277, § 139. 
Fair value. 
In determining what constitutes fair value 
under this section, consideration should be 
given to market value, investment value, and 
asset value. Oakridge Energy, Inc. v. Clifton. 
937R2d 130 (Utah 1997;. 
The trial court erred in using the stock mar-
ket price of shares as the sole criterion in 
determining fair value under this section: even 
though evidence of investment value was not 
presented, the court should at least have con-
sidered the asspt vfllno oo «T«n «~ <».i-- -
price of the stock in its valuation of dissenters' 
shares. Oakridge Energy, Inc. v. Clifton, 937 
R2d 130 (Utah 1997). 
Shareholders are entitled to receive the value 
of their holdings unaffected by the corporate 
action: thus, any effect of the sale of corporate 
assets had to be excluded in the determination 
of fair value, whether the effect occurred after 
the announcement of the sale, after the share-
holder vote, or as the result of retroactive 
provisions. Oakridge Energv, Inc. v. Clifton Q21 
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STANDARD OF VALUE 
The standard of value used m this appraisal \sfair value Fair value, as defined by the state of Utah, is the 
value of the shares immediately before the effectuation of the corporate action to which the dissenters 
object, excluding any appreciation or depreciation in anticipation of the corporate action 
H I G H E S T AND BEST USE ANALYSIS 
We appraised the common stock of Zmetics under the premise of value of the Zinetics operations in 
continued use, as a going concern business enterprise We have assumed that the management of the 
Company will continue to act in a prudent and responsible manner 
In our opinion, and based on our analysis, this premise of value represents the highest and best use of the 
subject securities 
SOURCES OF INFORMATION 
In the course of our analysis, we used financial and other information provided to us by Zinetics 
management and obtained from publicly available financial and industry sources we believed to be reliable 
The pnncipal sources of information upon which we relied in performing our valuation included, but were 
not limited to, the following 
• Zinetics Medical, Inc audited financial statements for fiscal years ended August 31, 1993 through 
1997, 
• Zinetics Medical, Inc internally prepared financial statements for the four months ended January 2, 
1998, and for the four months ended January 3, 1997, 
• Proposed Annual Contract for Products for Medtronics/Synectics dated August 1, 1997, 
• Zinetics Medical, Inc internally prepared cash flow projections, 
• Notice of Special Meeting of Zinetics Medical, Inc shareholders as of February 13, 1998, 
• Robert Morns Associates, Annual Statement Studies, 1997, 
• Ibbotson Associates, Stocks, Bonds, Bills, and Inflation, 1998 Yearbook; 
• Financial information (stock prices, shares outstanding, financial statements, profitability, etc) as 
of February 13, 1998, on U S publicly traded companies involved in the medical products industry 
We accessed various database services such as Standard & Poor's Corporation, Moody's, and 
others, and obtained vanous documents (annual reports, SEC Form 10-K's, SEC Form 10-Q's, etc ) 
filed with the Securities and Exchange Commission 
We also relied on the following sources in analyzing the U S economy The Wall Street Journal, Trends & 
Projections, Standard & Poor's Corporation, US Financial Data, Blue Chip Economic Indicators, 
m»ji Annnn^ 
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Barron s, Vie Oregoman, Business Week- US Bank Territory 1998 A Regional Economic Review and 
Forecast, and Reuters Limited 
FLNANCIAL STATEMENT ANALYSIS 
An important step in the valuation of any company is an analysis of its performance over time Past sales 
and earnings growth can provide an indication of future growth and can put the company's earnings in a 
histoncal context Other things being equal, a company with rapidly rising sales and earnings is worth more 
than one with little or no growth 
The following section examines the key trends in the Zinetics financial statements during the latest five-
year period ended August 31, 1997, and the latest twelve month period ended January 2, 1998 ("LTM 
period"), as presented in Appendix A 
Balance Sheets 
The Zinetics histoncal and common-size balance sheets as of August 31, 1993 through August 31, 1997, as 
well as for the intenm penod ended January 2, 1998, are presented on Exhibit I 
• From August 31, 1993 to January 2, 1998, total assets increased at a compounded annual growth 
rate of 30 5 percent, from $502,000 to $1 604 million 
• Total current assets increased from $413,000 as of August 31, 1993, to $1 413 million as of 
January 2, 1998 This was pnmanly due to an increase in cash and cash equivalents, which 
increased from $145,000 to $842,000 during this same penod Cash and cash equivalents 
represented 88 1 percent of total assets as of January 2, 1998 Overall, current assets have 
represented between 81 9 percent and 88 3 percent of total assets dunng the penod under review 
• Net fixed assets increased from $34,000 as of August 31, 1993, to $149,000 as of January 2, 
1998 The Zinetics manufactunng operations do not require substantial investment in capital 
equipment 
• Total liabilities decreased from $200,000 as of August 31, 1993, to $115,000 at January 2, 1998 
Total liabilities represented 7 2 percent of total assets as of January 2, 1998, after representing as 
much as 39 8 percent of total assets as of August 31, 1993 
• From August 31, 1993 to January 2, 1998, current liabilities decreased from $184,000 to 
$87,000 During this period, current liabilities decreased—as a percentage of total assets—from 
36 7 percent as of August 31, 1993, to 5 4 percent as of January 2, 1998 
• Obligation under capital leases declined from $37,000 at August 31, 1995—$23,000 of which 
was long-term—to $12,000 as of January 2, 1998—all of which was long-term 
• Total stockholders equity increased from $302,000 to $1 489 million during the observed penod 
This was due to the increase in retained earnings 
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Income Statements 
The Zinetics histoncal and common-size income statements for the fiscal years ending August 31, 1993 
through August 31, 1997, and for the LTM period are presented on Exhibit II 
• From fiscal 1993 through the LTM period, total revenues increased at a compounded annual 
growth rate of 19 3 percent, from $1213 million to S2 612 million 
• Gross profit margins—during the observed period—ranged from a low of 53 2 percent for the 
year ended August 31, 1993, to a high of 62 7 percent for the year ended August 31, 1997 The 
five-year average gross profit margin was 59 0 percent 
• Operating profit margins have fluctuated during the period under review, between a low of 9 3 
percent for fiscal 1996, and a high of 21 5 percent for fiscal 1994 The average operating profit 
margin for the observed period was 15 6 percent Operating income for the LTM period was 
5455,000, versus $184,000 for fiscal 1993, providing a compounded annual growth rate of 23 1 
percent 
• Net income for the LTM period totaled $435,000, up from fiscal 1993 net income of $153,000 
Net income has averaged 13 5 percent of net sales during the observed period, ranging from a low 
of 8 0 percent for fiscal 1995, to a high of 19 4 percent for fiscal 1997 
Financial and Operating Ratios 
Exhibit IV presents a summary of selected financial and operating ratios for Zinetics for the fiscal years 
ending August 31, 1993 through 1997, and for the LTM period 
• The current and quick ratios provide rough indications of the Zinetics ability to service its 
current obligations The Company's current and quick ratios have substantially increased during 
the period under review, to 16 2 and 13 5, respectively These ratios, combined with the Zinetics 
relatively large cash and cash equivalents balances, indicate that there may be more productive 
opportunities for some of the Company's current assets 
• Working capital is a measure of the margin of protection for current creditors The Zinetics 
working capital totaled $1 326 million at January 2, 1998, up significantly from prior years As 
previously discussed, the Company may not be fully utilizing some of its current assets 
• Activity ratios indicate how efficiently a company is utilizing its assets The Zinetics receivables 
turnover has increased—from 5 3 for fiscal 1994, to 8 3 for the LTM period—indicating more 
efficient collection of receivables The Company's inventory turnover, however, decreased from 
an observed period high of 11 1 for fiscal 1995, to 6 1 for the LTM period Zinetics operating 
cycle has been fairly consistent, ranging between 104 days and 113 days 
• The Zinetics profitability ratios indicate very strong returns on investments The Company's 
returns on average equity and on average total invested capital have observed period averages of 
37 6 percent and 36 8 percent, respectively 
,.mii/vnnn05 
Robert A Peterson Esq 
Octooer 16, 199& 
Page 5 
GENERAL ECONOMIC CONDITIONS AND INDUSTRY ANALYSIS 
In the valuation of a company, it is important to take into account the general economic and industry 
specific conditions in which the company is attempting to sell its products Accordingly, our valuation of 
Zmetics included a review of general U S economic conditions as well as the condition of the catheter 
industry as of February 13, 1998 
A summary of our U S economic analysis is provided in Appendix B Industry information used in our 
analysis is contained within our files 
MEDTRONIC ACQUISITION 
In March 1996, Medtronic acquired InSent Inc , a company that makes devices designed to prop open 
diseased arteries Although only two InSent products had been approved by the Food and Drug 
Administration at the time of the acquisition transaction, Medtronic paid approximately S214 6 million 
based on the InSent prior year revenues of S2 4 million, for a price/revenue multiple of 89 4 times 
Applying this price/revenue transactional multiple to the Zmetics revenues of S2 612 million for the latest 
twelve months ended January 2, 1998, yields a controlling ownership interest value of approximately 
S233 5 million Based on the 128,806,800 outstanding shares of Zmetics common stock, as of the Valuation 
Date, this calculation provides an indication of value of approximately SI 81 per share While we consider 
this value indication to be excessive, it does provide a market-denved indication of the investment value of 
the Zmetics common stock 
PUBLIC STOCK M A R K E T 
The Zmetics common stock is publicly traded on a non-NASDAQ over-the-counter stock exchange As 
such, the pnce paid for the shares of the stock, at any given time, reasonably reflects the marketable, 
minonty interest per share market value of the Zmetics common stock. 
The following table illustrates the Zmetics common stock pnce and value trading activity for the four 
months immediately preceding the Valuation Date 
Robert A Peterson, Esq 
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ZiNETlCS MEDICAL, INC 
COMMON STOCK PRICE AND VOLUME TRADING ACTIVITY 
10/13/97-2/13/98 
Date 
10/13/97 
10/15/97 
10/30/97 
11/3/97 
11/6/97 
11/10/97 
12/12/97 
1/7/98 
1/8/98 
2/10/98 
2/12/98 
Volume 
79,400 
5,000 
39,700 
325,900 
325,900 
35,000 
55,000 
5,000 
5,000 
20,000 
4,000 
High/Ask 
S 0 109 
0 078 
0 094 
0 125 
0 125 
0 094 
0 094 
0 109 
0 109 
0 141 
0 172 
Low/Bid 
S 0 109 
0 078 
0 094 
0 125 
0 125 
0 094 
0 078 
0 109 
0 109 
0 141 
0 172 
Close 
S 0 109 
0 078 
0 094 
0 125 
0 125 
0 094 
0 078 
0 109 
0 109 
0 141 
0 172 
As presented on the above table, the price of the subject common stock as of the Valuation Date was $0 172 
per share Based on the Company's 128,806,800 outstanding shares, this price provides a market-denved 
value and ratios of the Zmetics total common stock of S22 155 million 
While this indication of value is certainly noteworthy, we have not specifically included this market-denved 
valuation indication in our valuation synthesis and conclusion. Instead, we have decided to present these 
data as supporting evidence of our quantitative and qualitative valuation analyses. 
VALUATION APPROACHES 
This section of our report will discuss the general valuation methodologies used to estimate the fair value of 
the Zinetics common stock 
We considered the following generally accepted business valuation approaches and methods in our analysis 
Market Approach—Guideline Publicly Traded Company Method. This method uses the 
premise that the value of a business interest should be estimated based on what rational capital 
market investors would pay to own an equity interest in the subject company Capital market 
pncmg multiples (I e, P/E multiples) of publicly traded guideline companies are used to indicate 
the value of the subject equity interest 
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Market Approach—Guideline Merged and Acquired Company Method. The value of the 
business interest is estimated by comparing the subject business to guideline companies that 
themselves have been bought or sold during a reasonably recent period of time 
Income Approach—Discounted Cash Flow Method. This method is based on the premise that 
the value of a business interest is the present value of the future economic income to be derived by 
the owners of the business This method requires the following analyses revenue analysis, expense 
analysis, investment analysis, capital structure analysis, residual value analysis, and discount rate 
analysis (including assessment of company-specific business risk) 
Asset-Based Approach—Asset Accumulation Method. The value of all of the subject company's 
assets are discretely estimated and accumulated This method requires a discrete appraisal of the 
following* 
• current assets, 
• tangible real property, 
• tangible personal property, and 
• intangible assets, including going concern value and goodwill. 
Next, the current value of all of the company's liabilities is estimated. The value of the equity of the 
business enterpnse is the fair value of all of the assets less the fair value of all of the liabilities. 
For our analysis, we relied upon the following two generally accepted business valuation approaches and 
methods to estimate the fair value of the Zinetics common stock: 
1 market approach—the guideline publicly traded company method, and 
2 income approach—the discounted cash flow method 
Each of these two approaches to the estimation of fair value is discussed in the following sections 
The guideline merged and acquired company method was excluded from our analysis due to a lack of 
adequate market-derived transactional data. The asset accumulation method was excluded from our analysis 
because we did not have access to sufficient Company data in order to perform discrete appraisals of the 
individual company assets As mentioned above, in our opinion, the premise of value of the Zinetics 
operations in continued use, as a going concern business enterpnse, represents the highest and best use of 
the Zinetics secunties In addition, liquidation or other sale of the Company assets could only be 
consummated by a controlling ownership interest stockholder Minonty stockholders are unable to 
implement such an action. 
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The IVlarket Approach 
Guideline Publicly Traded Company Method 
As previously discussed, the guideline publicly traded company method estimates value based on the 
premise that the value of the subject business enterprise can be estimated based on what reasonably astute 
and rational capital market investors would pay to own the stock in the Company. 
Using this approach, the first step is to identify companies that are comparative to Zinetics in terms of 
business activities and financial status. Each of the guideline companies we selected are companies with 
securities that are publicly traded on an organized stock market exchange. A description of the guideline 
publicly traded companies used in our analysis, and the procedures performed to identify and select those 
companies, is provided in Appendix C. 
We calculated the market value of invested capital (MVIC) of each guideline company as of the Valuation 
Date. This value is estimated by adding the market value of interest-bearing debt (MVIBD) to the market 
value of equity capital (MVEC). The book value of interest-bearing debt is used as a reasonable 
approximation of MVIBD. MVEC is calculated by multiplying the price per share, as listed on the pertinent 
stock exchange on the Valuation Date, by the number of outstanding shares. 
Our calculation of the MVIC for the selected guideline publicly traded companies is set forth in Exhibit V. 
After calculating the MVIC of all the guideline companies, we calculated the pricing multiples of these 
companies' MVICs to their respective revenues. These valuation pricing multiples are referred to in this 
report as MVIC/revenues. 
A summary of our calculations used to estimate the valuation pricing multiples of the guideline companies 
are illustrated on Exhibit V. 
As this exhibit reflects, we analyzed the MVIC as compared with revenues on the basis of the latest twelve 
months and the five-year average. 
After calculating the valuation pricing multiples for each guideline publicly traded company, we then 
performed the following analysis: 
1. Calculate the low, high, mean and median of the guideline companies valuation pricing multiples. 
2. Review and analyze the historical financial performance of the guideline companies as compared to 
their respective valuation pricing multiples and attempt to identify positive or negative 
relationships. 
3. Compare the historical financial performance of Zinetics to the historical financial performance of 
the guideline companies for guidance in selecting appropriate valuation pricing multiples. 
4. Select appropriate valuation pricing multiples and apply them to the historical revenues of the 
Company. 
WMA00009 
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5. Subtract the long term interest-beanng debt from the indicated MVIC of Zinetics in order to 
estimate the Company's MVEC. 
Based on our analysis as discussed above, and in our opinion, the fair value of the total common stock of 
Zinetics, as indicated by the guideline publicly traded company method, on a marketable, minority 
ownership interest basis, as of the Valuation Date, is (rounded): $28,168 million. 
A summary of our guideline publicly traded company method analysis is provided on Exhibit VI. 
The common stock of Zinetics is publicly traded on an over-the-counter stock exchange The trading 
volume for this stock is very inconsistent, especially when compared to the volumes for the selected 
guideline publicly traded companies. 
Due to the deprivation nature of the action that gave rise to the above-mentioned litigation, we have been 
instructed by the counsel for the dissenting shareholders to value the subject stock assuming that it is a 
reasonably marketable and liquid investment. Therefore, we did not apply a discount for lack of 
marketability to our indicated value of the common stock of Zinetics. 
The Income Approach 
Discounted Cash Flow Method 
The income approach, using the discounted cash flow (DCF) method, requires a projection of the financial 
performance of the Company over future periods of time. The projected financial performance includes 
analyses of projected revenues, expenses, investment considerations, and residual value. 
Based on the results of these analyses, a projection of economic income (defined herein as net cash flow) 
from business operations is estimated for future periods. The resulting projection of cash flow is discounted 
at an appropriate present value discount rate ("discount rate11) to estimate the present value of the future 
cash flows. In our analysis, the discount rate is referred to as the required return on equity capital. Based on 
numerous empirical studies, we estimated the required rate of return on the Zinetics equity capital to be 20 
percent. 
In addition to estimating the present value of future earnings, the residual value of the business enterpnse is 
also estimated, i.e., the value of the enterpnse, as of the end of the discrete projection period. This residual 
value is discounted to estimate its present value, as of the valuation date as well. The present value of the 
cash flow projection is added to the present value of the residual value, which together represent the value 
of total invested capital of the business enterpnse. Lastly, the long-term interest-beanng debt is subtracted 
in order to estimate the market value of the subject common stock. 
Based on our analysis as discussed above, and in our opinion, the fair value of the total Zinetics common 
stock, as indicated by the discounted cash flow method, on a marketable, minonty ownership interest basis, 
as of the Valuation Date, was (rounded): $17,283 million. 
WMA00010 
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Summaries of our projections and of our DCF analysis for Zinetics are provided on Exhibits VII through 
XI. 
The indication of value provided by the DCF method estimates the value of the total common stock of the 
Company on a marketable, minority ownership interest basis for the following reasons* (1) the projected 
income statement was based on a reasonable expectation of the future financial performance of the 
Company and did not include changes that only a control owner could contemplate, and (2) the present 
value discount rate was derived from rates of return on minority ownership interest publicly traded 
securities. 
VALUATION SYNTHESIS 
As previously discussed, we used the following two approaches to estimate the value of the Zinetics 
common stock on a marketable, minority ownership interest basis: (1) the market approach, and (2) the 
income approach. The market approach and the income approach yielded (rounded) indicated values of 
S28.168 million and $17,283 million, respectively. We applied equal weights to the indications of value 
provided by the market approach and the income approach, respectively, in our analysis. 
Based on our analysis as described is this report, and in our opinion, the fair value of the total Zinetics 
Medical Inc. common stock, on a marketable, minority ownership interest basis, as of February 13, 1998, is 
(rounded): $22,726 million. 
VALUATION CONCLUSION 
As of the Valuation Date, there are 128,806,800 outstanding shares of Zinetics common stock. Based on our 
analysis as described in this report, and in our opinion, the fair value of the Zinetics Medical, Inc. total 
common stock on a marketable, minority ownership interest basis, as of February 13, 1998, was (rounded): 
S0.18 per share. 
A summary of our valuation synthesis and conclusion is provided on Exhibit XII. 
During our analysis, we were provided with both draft audited and internally prepared financial and 
operational data. We have relied upon these data, without independent venfication or confirmation, as 
accurately reflecting the operational and financial position of Zinetics. 
In accordance with guidelines set by the American Society of Appraisers, we are independent of Zinetics 
Medical, Inc. We have no current or prospective financial interest in Zinetics Medical, Inc. or any of its 
affiliates. Our fee for the appraisal was in no way influenced by the results of our valuation analysis. 
Robert A Peterson, Esq 
October 16, 1998 
Page 11 
The accompanying statement of contingent and limiting conditions, appraisal certification, and professional 
qualifications of the pnncipal analysts are integral parts of this valuation opinion. 
Very truly yours, 
WILLAMETTE MANAGEMENT ASSOCIATES 
Robert F. Reilly 
APPENDIX A 
EXHIBITS 
- * « 4 l 
EXHIBIT I 
ZINETICS MEDICAL, INC. 
HISTORICAL AND COMMON-SIZE BALANCE SHEETS 
As of 
1/2/98 
$000 
1997 
$000 
As of August 31 
1996 1995 
$000 $000 
1994 
$000 
1993 
$000 
As of 
1/2/98 
% 
1997 
As of August 31 
1996 
% 
1995 
% 
1994 
% 
1993 
% 
Assets 
Current Assets 
Cash and Cash equivalents 
Accounts Receivable Trade, Net 
Accounts Receivable - Related Parties 
Inventories 
Prepaid Expenses 
Total Current Assets 
I ixed Assets 
Furniture and Equipment 
Computers and Software 
Leasehold Improvements 
Leased Lquipment 
Total Fixed Assets, Gross 
Accumulated Depreciation 
Total Fixed Assets, Net 
842 
332 
10 
226 
4 
1,413 
303 
120 
30 
-
453 
(304) _ 
836 
133 
208 
219 
11 
1,408 
269 
112 
26 
22 
430 
(286) _ 
494 
116 
164 
116 
11 
901 
204 
83 
20 
56 _ 
363 
(230) _ 
277 
194 
221 
85 
24 
801 
182 
62 
16 
56 
315 
(188) _ 
208 
133 
250 
65 
20 
676 
167 
50 
109 
24 
349 
J282) _ 
145 
115 
86 
56 
11 
413 
173 
-
109 
24 
306 
(271) 
52 5 
20 7 
06 
14 1 
03 
88 1 
189 
75 
1 9 
-
28 3 
(190) 
52 4 
84 
13 1 
13 8 
07 
88 3 
169 
70 
1 6 
1 4 
27 0 
(180) 
45 7 
107 
152 
108 
1 0 
83 4 
189 
76 
1 9 
5 1 
33 6 
(213) 
28 3 
198 
22 6 
87 
24 
81 9 
186 
63 
1 6 
5 7 
32 2 
(19 2) 
26 0 
165 
31 2 
8 1 
25 
84 4 
20 8 
62 
136 
2 9 
43 3 
(33 3) 
28 9 
22 9 
172 
11 2 
23 
82 4 
34 5 
-
21 7 
4 7 
60 9 
_J>4_0) 
149 144 133 127 66 34 9 3 9 0 123 130 83 6 9 
Other Assets 
Intangible Asset*, Net 
Deposits - Workers' Compensation 
Deferred Income Taxes 
Total Other Assets 
Total Assets 
16 
I 
24 
41 
1 604 
17 
1 
24 
43 
1 594 
21 
I 
24 
46 
I 080 
25 
I 
24 
50 
978 
30 
2 
26 
59 
801 
34 
2 
18 
1 0 
0 1 
1 5 
1 I 
0 1 
1 3 
1 9 
0 1 
22 
23 
0 1 
2 3 
37 
03 
33 
6 7 
0 S 
3 3 
34 
502 
2 6 
100 0 
2 7 
100 0 
4 3 
100 0 
3 1 
100 0 
73 
100 0 
107 
100 0 
Sources Compmy audited and internally prepared (unaudited) financial statements as presented 
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EXHIBIT I 
ZINETICS MEDICAL, INC. 
HISTORICAL AND COMMON-SIZE BALANCE SHEETS 
As of 
1/2/98 1997 
$000 $000 
As of August 31, 
1996 
$000 
1995 
$000 
1994 
$000 
1993 
$000 
As of 
1/2/98 
% 
1997 
% 
As of August 31, 
1996 
% 
1995 
% 
1994 
% 
1993 
% 
1 labilities and Stockholder's Equity 
Current Liabilities 
Note Payable 
Current Portion Under Capital Leases 
Due to Stockholder 
Accounts Payable 
Accrued Expenses 
Income Taxes Payable 
lotal Current Liabilities 
Other Liabilities 
Obligation Under Capital Leases 
Deferred Income Taxes 
Total Other Liabilities 
Total Liabilities 
Stockholder's Cquity 
Common Stock 
Additional Paid-in Capital 
Retained Earnings 
Treasury Stock 
Total Stockholder's Cquity 
Total Liabilities and Stockholders' Equity 
-
-
-
34 
45 
8 
87 
12 
15 
27 
115 
129 
48 
1,322 
(10) _ 
1,489 
1,604 
7 
6 
-
28 
74 
55 
170 
8 
15 
23 
194 
129 
48 
1,234 
(10) __ 
1,400 
1,594 
7 
8 
17 
23 
64 
17 
136 
15 
9 
24 
161 
129 
48 
753 
00) _ 
920 
1,080 
9 
14 
52 
22 
103 
-
199 
23 
7 
31 
229 
129 
48 
582 
00) _ 
749 
978 
9 
6 
31 
45 
109 
-
200 
9 
5 
14 
215 
129 
48 
420 
(10) _ 
586 
801 
3 
5 
82 
16 
79 
-
184 
15 
-
15 
200 
129 
48 
136 
00) 
302 
502 
-
-
-
2 1 
28 
0_5 
54 
08 
I 0 
1 7 
72 
80 
30 
82 5 
(0 6) 
92 8 
100 0 
04 
04 
-
I 8 
4 7 
34 
107 
05 
i 0 
1 5 
122 
8 1 
30 
77 4 
(0 6) 
87 8 
100 0 
06 
08 
1 6 
22 
59 
1 6 
126 
1 4 
0£ 
22 
149 
11 9 
44 
69 7 
(0 9) 
85 1 
100 0 
0 9 
1 4 
53 
22 
105 
-
20 3 
24 
07 
3 1 
23 4 
132 
49 
39 5 
(10) 
76 6 
100 0 
1 1 
08 
39 
5 7 
136 
-
23 0 
1 2 
06 
1 8 
26 8 
16 1 
60 
52 4 
(12) 
73 2 
100 0 
06 
1 0 
163 
32 
13 7 
-
36 7 
3 1 
-
3 1 
39 8 
25 7 
95 
27 0 
(2 0) 
60 2 
100 0 
Sources: Company audited and internally prepared (unaudited) financial statements as presented 
P.ifc 2 o l 2 
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EXHIBIT II 
ZINETICS MEDICAL, INC. 
HISTORICAL AND COMMON-SIZE INCOME STATEMENTS 
Total Revenues 
Cost of Sales 
Gross Profit 
Operating Expenses 
Selling, General & Administrative 
Research and Development 
Depreciation and Amortization 
Total Operating Expenses 
Operating Income 
Other Income (Expenses), Net 
Interest Expense 
Interest Income 
Bad Debt Expense and Other Adjustments 
Total Other Income (Expenses), Net 
LTM 
Ending 
1/2/98 
$000 
2,612 
1,035 
1,577 
1,046 
II 
65^  
1,122 
455 
(1) 
39 
(2) . 
36 
1997 
$000 
2,476 
924 
1,551 
998 
11 
60 
1,070 
482 
(1) 
33 
(2) . 
30 
As 
1996 
$000 
1,890 
795 
1,095 
866 
8 
46 
920 
175 
(3) 
15 
(2) . 
11 
of August 31, 
1995 
$000 
2,042 
836 
1,206 
899 
11 
953 
253 
(16) 
0 
(9) _ 
(24) 
1994 
$000 
1,542 
588 
954 
607 
-
622 
332 
(ID 
-
(11) 
1993 
$000 
1,213 
568 
645 
448 
-
13 
462 
184 
(13) 
-
07) 
(30) 
LIM 
Ending 
1/2/98 
% 
100 0 
39 6 
60 4 
40 1 
04 
2J1 
43 0 
174 
(0 0) 
1 5 
(0 1) 
1 4 
1997 
% 
100 0 
37 3 
62 7 
40 3 
04 
24 
43 2 
195 
(0 0) 
1 3 
(0 1) 
I 2 
As ( 
1996 
% 
100 0 
42 1 
57 9 
45 8 
04 
24 
48 7 
93 
(0 2) 
08 
(0 1) 
06 
)f August 
1995 
% 
100 0 
40 9 
59 1 
44 0 
06 
2 1 
46 7 
124 
(0 8) 
0 0 
(0 4) 
(12) 
31. 
1994 
% 
100 0 
38 I 
61 9 
39 3 
-
1 0 
40 3 
21 5 
(0 7) 
-
-
(0 7) 
1993 
% 
100 0 
46 8 
53 2 
37 0 
-
1 1 
38 0 
152 
(1 I) 
-
(14) 
(2 5) 
Extraordinary Item 
Recovery of Unauthorized Withdrawals 13 13 14 14 14 14 05 05 08 07 09 1 1 
Pretax Income 
Total Income Taxes 
Net Income 
504 
69 
435 
525 
44 
481 
200 
29 
171 
244 
81 
162 
336 
52 
284 
167 
14 
153 
193 
26 
167 
21 2 
I 8 
194 
106 
1 5 
9 I 
11 9 
4 0 
80 
21 8 
34 
18 4 
13 8 
1 2 
12 6 
Source. Company audited and internally prepared (unaudited) financial statements as presented 
EXHIBIT III 
ZINETICS MEDICAL, INC. 
HISTORICAL STATEMENTS OF CASH FLOW 
\s ot August 31 
1997 1996 1995 1994 1993 
S000 S000 $000 S000 S000 
Cash Flow from Operating Activities 
Net Income 
Adjustments to Reconcile Net Income to Cash Flow 
from Operating Activities 
Depreciation and Amortization 
Loss on Disposition of Assets 
Cash Provided from Operations 
Changes in Assets and Liabilities 
Accounts Receivable 
Inventory 
Prepaids 
Other Assets 
Accounts Payable 
Accrued Expenses 
Deferred Taxes 
Cash Flow from Operating Activities 
Cash Flow from Investing Activities 
Captital Expenditures 
Cash Flow from Investing Activities 
Cash Flow from Financing Activities 
Payment on Notes Payable to Stockholder 
Proceeds (Payments) on Notes Payable and Leases Payable 
Cash Flow from Financing Activities 
Increase (Decrease) in Cash and Equivalents 
Cash and Equivalents, Beginning of Year 
Cash and Equivalents, End of Year 
481 
418 
171 
290 
162 284 
60 46 43 15 
I 
541 217 206 299 
169 157 
153 
13 
166 
(62) 135 (32) (182) (80) 
(103) 
(0) 
-
(12) 
48 
6 
(3D 
13 
-
(23) 
(22) 
2 
(20) 
(4) 
2 
18 
(6) 
5 
(9) 
(8) 
-
29 
(25) 
51 
21 
(2) 
-
(28) 
44 
-
121 
(67) (48) (101) (43) (34) 
(67) (48) (101) (43) (34) 
(10) (21) (51) (8) 
(9) (15) 22 1 13 
(9) _ 
342 
494 
836 
(25) _ 
217 
277 
494 
0 
68 
208 
277 
(50) _ 
64 
145 
208 
5 
92 
53 
145 
Sources- Company audited financial statements as presented 
EXHIBIT IV 
ZINETICS MEDICAL, INC. 
RATIO ANALYSIS 
LIQUIDITY 
Current Ratio 
Quick Ratio 
Operating Working Capital (S000) 
Non-Cash Working Capital ($000) 
Total Working Capital (S000) 
Acnvm 
Turnover 
Working Capital 
Receivables 
Inventory 
Total Asset 
Average Collection Period (Days) 
Days to Sell Inventory 
Operating Cycle (Days) 
Deprecianon/PY Net PP&E (%) 
Depreciation/PY Gross PP&E (%) 
Average Operating Working CapitaJ/Sales (%) 
Average Non-Cash Working Capital/Sales (%) 
Cap E\/PY Net PP&E (%) 
PERFORMANCE 
Sales/Net Property, Plant & Equipment 
Sales/Stockholder Equity 
PROFITABILITY (%) 
Operating Margin Before Depreciation 
Operating Margin After Depreciation 
Pretax Profit Margin 
Net Profit Margin 
Return on 
Assets 
Average Assets 
Equity 
Average Equity 
Total Invested Capital 
Average Total Invested Capital 
LEVERAGE 
Interest Coverage Before Tax 
Interest Coverage After Tax 
Long-Term Debt/Shareholders' Equity (%) 
Total Debt/Invested Capital (%) 
Total Debt/Total Assets (%) 
LTM 
Ending 
1/2/98 
162 
135 
537 
484 
1,326 
2.5 
8.4 
6.1 
1.9 
43 
60 
104 
16.9 
62 
20 7 
17.0 
NM 
18.5 
2.2 
18.3 
17.4 
19.3 
16.7 
27.1 
32.4 
29.2 
30.1 
29 0 
35.7 
733 0 
632 7 
08 
08 
0.8 
1997 
83 
69 
544 
402 
1,238 
2.5 
8.0 
5.5 
1.9 
46 
66 
112 
45.5 
167 
18.7 
136 
50.5 
17.9 
2.1 
21.9 
19.5 
21.2 
19.4 
30.1 
35.9 
34.3 
41.4 
34.1 
41.0 
591.1 
541 5 
06 
1 5 
1.3 
As of August 3! 
1996 
66 
57 
384 
271 
765 
2.8 
5.4 
7.9 
1.8 
67 
46 
113 
35.9 
145 
23 4 
15 8 
37.7 
14.5 
2.3 
11.7 
9.3 
10.6 
9.1 
15.8 
16.6 
18.6 
20.5 
183 
20.1 
65.3 
56.0 
I 7 
32 
28 
1995 
40 
35 
502 
325 
602 
3.8 
5.1 
11.1 
2.3 
71 
33 
104 
64.7 
12.3 
22.6 
145 
151 7 
21.1 
3.1 
14.5 
12.4 
11.9 
8.0 
16.6 
183 
21.7 
24.3 
21.0 
23.7 
16.5 
11 3 
3 1 
58 
47 
I, 
1994 
34 
30 
422 
267 
475 
44 
5.3 
9.7 
2.4 
69 
38 
107 
43.9 
4 9 
21.9 
11 4 
125 4 
30.6 
3.5 
22.5 
21.5 
21.8 
18.4 
35.5 
43.6 
48.5 
64.0 
47.7 
62.2 
32.5 
27 6 
16 
40 
30 
1993 
22 
I 9 
253 
84 
229 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
NM 
162 
152 
138 
126 
30 5 
NM 
50 7 
NM 
48 2 
NM 
138 
127 
5 I 
72 
47 
Sources: Exhibits I & II and WMA calculations. 
EXHIBIT V 
ZINETICS MEDICAL, INC. 
MARKET APPROACH 
GUIDELINE PUBLICLY TRADED COMPANY METHOD 
MARKET VALUE OF INVESTED CAPITAL 
Company kt /Sym 
OTC 
NASDAQ 
NASDAQ 
NASDAQ 
OTC 
NASDAQ 
NASDAQ 
NASDAQ 
NASDAQ 
NASDAQ 
NASDAQ 
FYE 
Dec-96 
Jul-97 
Dcc-96 
Dec-96 
Aug-97 
Dec-96 
Jun-97 
Dec-97 
Mar-97 
Jul-97 
Sep-97 
TBV 
$000 
4,712 
25,751 
49,551 
42,228 
(428) 
42,124 
3,133 
2,699 
37,657 
13,705 
32,254 
Latest Quarter 
BVIBD 
$000 
847 
-
-
-
2,106 
-
-
747 
211 
195 
-
TBVIC 
$000 
5,559 
25,751 
49,551 
42,228 
1,678 
42,124 
3,133 
3,446 
37,868 
13,899 
32,254 
MVlBD[a] 
$000 
847 
-
-
-
2,106 
-
-
747 
211 
195 
-
As of 
or for 
Period 
Ending 
Sep-97 
Dec-97 
Sep-97 
Sep-97 
Nov-97 
Sep-97 
Dec-97 
Dec-97 
Dec-97 
Jan-98 
Dec-97 
Bid/Close 
Price Per 
Common 
Share 
2/13/98 
$ 
0 344 
2 938 
7 375 
5 125 
0 460 
10 125 
3 125 
2 625 
24 000 
13 125 
15 250 
Common 
Shares 
Outstg [b] 
000s 
17,328 
32,998 
12,066 
9,371 
6,384 
16,148 
3,238 
4,112 
10,665 
12,209 
5,262 
Market Value of Equity 
Common 
$000 
5,956 
96,949 
88,984 
48,026 
2,936 
163,495 
10,118 
10,795 
255,951 
160,243 
80,238 
Preferred 
$000 
4,505 
-
-
-
-
-
-
-
-
-
-
MV1C 
$000 
11,308 
96,949 
88,984 
48,026 
5,042 
163,495 
10,118 
11,542 
256,162 
160,437 
80,238 
American Biomed Inc 
Angeion Corp 
Cardiogenesis Corp 
Cardiovascular Dynamics 
Electro Catheter Corp 
Endosonics Corp 
Luther Medical Products 
Medamicus Inc 
Perclose Inc 
Possis Medical Inc 
Rochester Medical 
Zinetics Medical, Inc OTC Aug-97 1,473 12 1,485 12 Jan-98 0 172 128,807 22,139 22,151 
Definitions, sources, and footnotes are found on the final page of Exhibit V 
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EXHIBIT V 
ZINETICS MEDICAL, INC. 
MARKET APPROACH 
GUIDELINE PUBLICLY TRADED COMPANY METHOD 
EARNINGS BEFORE INTEREST AND TAXES 
Company 
American Biomed Inc 
Angeion Corp 
Cardiogenesis Corp 
Cardiovascular Dynamics 
Electro Catheter Corp 
Endosonics Corp 
Luther Medical Products 
Medamicus Inc 
Perclose Inc 
Possis Medical Inc 
Rochester Medical 
LOW 
HIGH 
MEAN 
MEDIAN 
LTM 
EDIT 
$000 
(2,376) 
(34,055) 
(15,555) 
(4,632) 
(934) 
(947) 
(439) 
(982) 
(15,237) 
(11,042) 
(1,825) 
Ending 
9/97 
12/97 
9/97 
9/97 
11/97 
9/97 
12/97 
12/97 
12/97 
1/98 
12/97 
1997/6 
$000 
(2,311) 
(26,805) 
(8,800) 
(3,224) 
(659) 
(5,024) 
(729) 
(982) 
(9,541) 
(8,602) 
(1,757) 
Earnings Before 
Interest &. Taxes (CB1T) 
1996/5 
$000 
(1,008) 
(15,065) 
(5,299) 
(2,874) 
(682) 
(9,984) 
(718) 
(232) 
(7,918) 
(8,564) 
(1,075) 
1995/4 
$000 
(3,604) 
(9,372) 
(1,784) 
(971) 
(968) 
(10,929) 
2,659 
(1,153) 
(6,934) 
(5,129) 
(1.243) 
1994/3 
$000 
(6,887) 
(7,515) 
-
-
(1,479) 
(7,050) 
(536) 
(1,277) 
(2,610) 
(599) 
(925) 
1993/2 
$000 
(4,292) 
(5,840) 
-
-
(756) 
0,553) 
244 
(769) 
(608) 
(1,369) 
(600) 
5-Year 
Average [c] 
EDIT 
$000 
(3,237) 
(12,919) 
(6,288) 
(2,340) 
(909) 
(6,787) 
48 
(883) 
(8,448) 
(6,787) 
(1,120) 
5-Ycar 
Average 
Annual 
Compound 
Growth [d] 
% 
(11 7) 
49 0 
#DlV/0' 
#DlV/0i 
5 1 
(24 3) 
#NUM! 
63 
96 6 
58 9 
29 9 
//DIV/0' 
0DIV/O' 
0D1V/O' 
#DlV/0» 
MVIC 
$000 
11,308 
96,949 
88,984 
48,026 
5,042 
163,495 
10,118 
11,542 
256,162 
160,437 
80,238 
MVIC/I BIT 
LIM 
(4 8) 
(2 8) 
(5 7) 
(104) 
(5 4) 
(172 6) 
(23 1) 
(II 8) 
(168) 
(14 5) 
(44 0) 
(172 6) 
(2 8) 
(28 4) 
(118) 
5-Year 
Average 
(3 5) 
(7 5) 
(14 2) 
(20 5) 
(5 5) 
(24 1) 
2126 
(13 1) 
(30 3) 
(23 6) 
(716) 
(71 6) 
2126 
(0 1) 
(14 2) 
Zinetics Medical, Inc 493 1/98 514 188 238 322 171 286 27 6 22,151 NM NM 
Definitions, sources, and footnotes are found on the final page of Exhibit V 
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EXHIBIT V 
ZINETICS MEDICAL, INC. 
MARKET APPROACH 
GUIDELINE PUBLICLY TRADED COMPANY METHOD 
EARNINGS BEFORE DEPRECIATION, INTEREST, AND TAXES 
Company 
American Biomed Inc 
Angeion Corp 
Cardiogencsis Corp 
Cardiovascular Dynamics 
Electro Catheter Corp 
Endosonics Corp 
Luther Medical Products 
Medamicus Inc 
Perclose Inc 
Possis Medical Inc 
Rochester Medical 
LOW 
HIGH 
MEAN 
MEDIAN 
LTM 
EBDIT 
$000 
(2.042) 
(32.009) 
(14.663) 
(4.213) 
(779) 
I 
(222) 
(580) 
(14.273) 
(10,439) 
(1.221) 
Ending 
9/97 
12/97 
9/97 
9/97 
11/97 
9/97 
12/97 
12/97 
12/97 
1/98 
12/97 
1997/6 
$000 
(1.977) 
(25.005) 
(7,641) 
(2,923) 
(505) 
(4,406) 
(495) 
(580) 
(8.872) 
(8,056) 
(1,218) 
Earnings 
Amortization, 
1996/5 
$000 
(347) 
(14,059) 
(5,081) 
(2,312) 
(543) 
(9,569) 
(536) 
60 
(7,246) 
(8,097) 
(597) 
Before Depreciation & 
Interest, & Taxes (EBDI T) 
1995/4 
$000 
(2,889) 
(8,774) 
(1,744) 
(953) 
(769) 
(9,894) 
2,854 
(850) 
(6,597) 
(4,696) 
(897) 
1994/3 
$000 
(6,237) 
(5,563) 
-
-
(1,311) 
(6,716) 
(363) 
(1,019) 
(2,549) 
(173) 
(590) 
1993/2 
$000 
(3,964) 
(5,423) 
-
-
(614) 
(3,221) 
390 
(581) 
(608) 
(787) 
(297) 
5-Year 
Average [c] 
LBDIT 
$000 
(2,698) 
(11,765) 
(5,826) 
(2,080) 
(749) 
(6.117) 
247 
(594) 
(7,907) 
(6,292) 
(720) 
5-Year 
Average 
Annual 
Compound 
Growth (d) 
% 
(13 0) 
49 4 
#DIV/0' 
#DlV/0i 
57 
#NUM« 
#NUM» 
(0 1) 
94 0 
77 4 
39 4 
#DIV/0' 
#DlV/0' 
#DlV/0» 
#DlV/0' 
MVIC 
$000 
11.308 
96.949 
88.984 
48.026 
5.042 
163.495 
10.118 
11,542 
256.162 
160.437 
80,238 
MVIC/I BDll 
L1M 
(5 5) 
(3 0) 
(6 1) 
(114) 
(6 5) 
163,495 2 
(45 7) 
(19 9) 
(179) 
(1^4) 
(6>7) 
(65 7) 
163.495 2 
14,845 3 
(114) 
5-Year 
Average 
(4 2) 
(8 2) 
(153) 
(23 1) 
(6 7) 
(26 7) 
40 9 
(194) 
(32 4) 
(25 5) 
(1114) 
(1114) 
40 9 
(21 1) 
(194) 
Zinetics Medical, Inc 558 1/98 574 233 281 337 184 322 29 1 NM NM NM 
Definitions, sources, and footnotes are found on the final page of Exhibit V 
WMA00021 
EXHIBIT V 
ZINETICS MEDICAL, INC. 
MARKET APPROACH 
GUIDELINE PUBLICLY TRADED COMPANY METHOD 
DEBT-FREE NET INCOME 
Company 
L1M 
DFNI 
$000 
(2,376) 
(34,055) 
(15,555) 
(4,632) 
(934) 
(947) 
(439) 
(982) 
(15,237) 
(11,042) 
(1,825) 
Ending 
9/97 
12/97 
9/97 
9/97 
11/97 
9/97 
12/97 
12/97 
12/97 
1/98 
12/97 
1997/6 
$000 
(2,311) 
(26,805) 
(8,800) 
(3,224) 
(659) 
(5,024) 
(730) 
(982) 
(9,541) 
(8,602) 
(1,757) 
Debt-Free Net Income 
1996/5 
$000 
(1,008) 
(15,065) 
(5,299) 
(2,874) 
(682) 
(9,984) 
(719) 
(232) 
(7,918) 
(8,564) 
(1,075) 
1995/4 
$000 
(3,604) 
(9,372) 
(1,784) 
(971) 
(968) 
(10,929) 
2,531 
(U53) 
(6.934) 
(5.129) 
(1,243) 
1994/3 
$000 
(6,887) 
(7,515) 
-
-
(1,479) 
(7,050) 
(537) 
(1,277) 
(2,610) 
(599) 
(925) 
1993/2 
$000 
(4,292) 
(5,840) 
-
-
(756) 
(3,553) 
243 
(769) 
(608) 
(1,369) 
(600) 
5-Year 
Average [c] 
DrNI 
$000 
(3,237) 
(12,919) 
(6,288) 
(2,340) 
(909) 
(6,787) 
21 
(883) 
(8,448) 
(6,787) 
(1.120) 
5-Year 
Average 
Annual 
Compound 
Growth [d] 
% 
(11 7) 
49 0 
0D1V/O' 
0DIV/O' 
5 1 
(24 3) 
#NUM« 
63 
96 6 
58 9 
29 9 
#DIV/0« 
#DIV/0» 
#DIV/0' 
#DIV/0« 
MVIC 
$000 
11,308 
96,949 
88,984 
48,026 
5,042 
163,495 
10,118 
11,542 
256,162 
160,437 
80,238 
MVIC/DFNI 
LIM 
(4 8) 
(2 8) 
0 7) 
(104) 
(5 4) 
(172 6) 
(23 0) 
(118) 
(168) 
(14 5) 
(44 0) 
(172 6) 
(2 8) 
(28 3) 
(118) 
5-Year 
Average 
(3 3) 
(7 5) 
(14 2) 
(20 5) 
(5 5) 
(24 1) 
476 8 
(13 1) 
(30 3) 
(23 6) 
(71 6) 
(716) 
476 8 
23 9 
(14 2) 
American Biomed Inc 
Angeion Corp 
Cardiogenesis Corp 
Cardiovascular Dynamics 
Electro Catheter Corp 
Endosomcs Corp 
Luther Medical Products 
Medanucus Inc 
Perclose Inc 
Possis Medical Inc 
Rochester Medical 
LOW 
HIGH 
MEAN 
MEDIAN 
Zinetics Medical, Inc 424 1/98 471 160 158 272 156 244 25 8 NM NM N M 
Definitions, sources, and footnotes are found on the final page of Exhibit V 
l / \ /A/lAnnrio#* 
EXHIBIT V 
ZINETICS MEDICAL, INC. 
MARKET APPROACH 
GUIDELINE PUBLICLY TRADED COMPANY METHOD 
DEBT-FREE CASH FLOW 
5-Year 
Average 
5-Year Annual MVIC/Dl CI 
LTM Debt-Free Cash How Average (c) Compound LIM 5-Year 
Company DITT Ending 1997/6 1996/5 1995/4 1994/3 1993/2 DICI Growth [d] MVIC Average 
$000 $000 $000 $000 $000 $000 $000 % $000 
American Biomcd Inc 
Angeion Corp 
Cardiogenesis Corp 
Cardiovascular Dynamics 
Llectro Catheter Corp 
Endosonics Corp 
Luther Medical Products 
Medamicus Inc 
Perclose Inc 
Possis Medical Inc 
Rochester Medical 
LOW 
HIGH 
MEAN 
MEDIAN 
(2,042) 
(32,009) 
(14,663) 
(4,213) 
(779) 
I 
(222) 
(580) 
(14,273) 
(10,439) 
(1,221) 
35,703 
35,795 
35,703 
35,703 
35,764 
35,703 
35,795 
35,795 
35,795 
35,826 
35,795 
(1,977) 
(25,005) 
(7,641) 
(2,923) 
(505) 
(4,406) 
(496) 
(580) 
(8,872) 
(8,056) 
(1,218) 
(347) 
(14,059) 
(5,081) 
(2,312) 
(543) 
(9,569) 
(537) 
60 
(7,246) 
(8,097) 
(597) 
(2,889) 
(8,774) 
(1,744) 
(953) 
(769) 
(9,894) 
2,725 
(850) 
(6,597) 
(4,696) 
(897) 
(6,237) 
(5,563) 
-
-
(1.311) 
(6,716) 
(364) 
(1,019) 
(2,549) 
(173) 
(590) 
(3,964) 
(5,423) 
-
-
(614) 
(3,221) 
389 
(581) 
(608) 
(787) 
(297) 
(2,698) 
(11,765) 
(5,826) 
(2,080) 
(749) 
(6,117) 
221 
(594) 
(7,907) 
(6,292) 
(720) 
(13 0) 
49 4 
#DIV/0« 
#DIV/0« 
57 
#NUM' 
#NUM» 
(0 1) 
94 0 
77 4 
39 4 
tIDlV/Qt 
#DIV/0» 
#DIV/0» 
#DIV/0i 
11,308 
96,949 
88,984 
48,026 
5,042 
163,495 
10,118 
II 542 
236,162 
160,437 
80,238 
(5 3) 
(3 0) 
(6 1) 
(114) 
(6 5) 
ttHtiHtitttt 
(45 3) 
(199) 
(17 9) 
(154) 
(63 7) 
(65 7) 
####### 
14,84} 3 
(114) 
(4 2) 
(8 2) 
(153) 
(23 1) 
(6 7) 
(26 7) 
4!) 8 
(194) 
(32 4) 
(233) 
(III 4) 
(1114) 
4!> 8 
(20 7) 
(194) 
Zmetics Medical, Inc 489 1/98 531 206 201 287 170 279 27 6 NM NM NM 
Definitions, sources, and footnotes are found on the final page of Lxhibit V 
WMA00023 
EXHIBIT V 
ZINETICS MEDICAL, INC. 
MARKET APPROACH 
GUIDELINE PUBLICLY TRADED COMPANY METHOD 
REVENUES 
Company 
LTM 
Revenues 
$000 
523 
3,094 
6,500 
11,491 
6,306 
29,833 
5,962 
7,173 
5,821 
5,114 
7,743 
Lnding 
9/97 
12/97 
9/97 
9/97 
11/97 
9/97 
12/97 
12/97 
12/97 
1/98 
12/97 
1997/6 
$000 
580 
4,505 
3,959 
8.734 
6,648 
24,373 
5,477 
5,660 
4,456 
4,834 
7,615 
1996/5 
$000 
661 
2,949 
-
4,103 
7,362 
17,137 
4,022 
5,295 
2,457 
1,606 
5,540 
Revenues 
1995/4 
$000 
637 
-
-
2,3X9 
7,263 
8,018 
7,354 
3,011 
178 
3,207 
3,131 
1994/3 
$000 
827 
-
-
-
7,248 
4,665 
2,251 
2,008 
-
6,400 
2,189 
1993/2 
$000 
610 
138 
-
-
8,155 
5,092 
2,798 
2,326 
-
8,435 
1,393 
5-Year 
Average [c] 
Revenues 
$000 
645 
1,518 
2,092 
S343 
7,335 
16,805 
5,013 
3,660 
2,582 
4,232 
3,974 
5-Year 
Average 
Annual 
Compound 
Growth [d] 
% 
(3 2) 
NM 
NM 
NM 
(5 9) 
45 0 
183 
32 5 
NM 
(10 5) 
49 7 
(10 5) 
49 7 
180 
183 
MV1C 
$000 
11,308 
96,949 
88,984 
4K 026 
5,042 
163,495 
10,118 
11,542 
256,162 
160,437 
80,238 
MVIC/ " 
Revenues 
LTM 
21 62 
31 33 
13 69 
4 18 
0 80 
5 48 
1 70 
1 61 
44 01 
31 37 
10 30 
0 80 
44 01 
1> 11 
10 36 
5-Year 
Average 
17 52 
63 85 
42 54 
8 99 
0 69 
9 73 
2 02 
3 IS 
99 20 
3791 
20 19 
0 69 
99 20 
27 80 
17 :>2 
American Biomed Inc 
Angeion Corp 
Cardiogcnesis Corp 
Cardiovascular Dynamic* 
Electro Catheter Corp 
Endosomcs Corp 
Luther Medical Products 
Medamicus Inc 
Perclose Inc 
Possis Medical Inc 
Rochester Medical 
LOW 
HIGH 
MLAN 
MCDIAN 
Zinelics Medical, Inc 2,612 1/98 2,476 1,890 2,042 1,542 1,213 1,833 193 22,151 8 48 12 09 
Definitions, sources, and footnotes are found on the final page of Exhibit V 
EXHIBIT V 
ZINETICS MEDICAL, INC. 
MARKET APPROACH 
GUIDELINE PUBLICLY TRADED COMPANY METHOD 
REVENUE PERFORMANCE RATIOS 
LTM Return on Revenues 5 Year Average Return on Revenues 
Company LBIT EBD1T DINI DI CI LBIT LBD11 DINI DI CI 
% % % % % % % % 
American Biomed Inc 
Angeion Corp 
Cardiogenesis Corp 
Cardiovascular Dynamics 
Electro Catheter Corp 
Endosonics Corp 
I uther Medical Products 
Medanucus Inc 
Perclobe Inc 
Possis Medical Inc 
Rochester Medical 
IOW 
HIGH 
MEAN 
MLDIAN 
(454 3) 
(1,100 6) 
(239 3) 
(40 3) 
(14 8) 
(3 2) 
(7 4) 
(13 7) 
(261 8) 
(215 9) 
(23 6) 
(1,1006) 
(3 2) 
(215 9) 
(40 3) 
(390 4) 
(1,034 5) 
(225 6) 
(36 7) 
(123) 
0 0 
(3 7) 
(8 1) 
(245 2) 
(204 1) 
(15 8) 
(1,034 5) 
0 0 
(197 9) 
(36 7) 
(454 3) 
(1,1006) 
(239 3) 
(40 3) 
(14 8) 
(3 2) 
(7 4) 
(13 7) 
(261 8) 
(215 9) 
(23 6) 
(1,100 6) 
(3 2) 
(215 9) 
(40 3) 
(390 4) 
(1,034 5) 
(225 6) 
(36 7) 
(12 3) 
0 0 
(3 7) 
(8 1) 
(245 2) 
(204 I) 
(15 8) 
(1,034 D) 
0 0 
(197 9) 
(36 7) 
(501 5) 
(850 9) 
(300 6) 
(43 8) 
(124) 
(40 4) 
0 9 
(24 1) 
(327 1) 
(1604) 
(28 2) 
(850 9) 
0 9 
(208 0) 
(43 8) 
(418 1) 
(774 8) 
(278 5) 
(38 9) 
(102) 
(36 4) 
4 9 
(162) 
(306 2) 
(148 7) 
(18 1) 
(774 8) 
4 9 
(183 6) 
(38 9) 
(501 5) 
(850 9) 
(300 6) 
(43 8) 
(124) 
(40 4) 
04 
(24 1) 
(327 1) 
(1604) 
(28 2) 
(850 9) 
0 4 
(208 1) 
(43 8) 
(418 1) 
(774 8) 
(278 5) 
(38 9) 
(102) 
(36 4) 
4 4 
(162) 
(306 2) 
(148 7) 
(18 1) 
(774 8) 
44 
(18^ 6) 
(38 9) 
/inches Medical Inc 189 213 162 187 156 176 133 l> 2 
Definitions, sources, and footnotes are found on the final page of Exhibit V 
EXHIBIT V 
ZINETICS MEDICAL, INC. 
MARKET APPROACH 
GUIDELINE PUBLICLY TRADED COMPANY METHOD 
BOOK VALUE OF INVESTED CAPITAL AND PERFORMANCE RATIOS 
Company MVIC 
$000s 
11,308 
96,949 
88,984 
48,026 
5,042 
163,495 
10,118 
11,542 
256,162 
160,437 
80,238 
MVIC/ 
Lat Qtr 
TBVIC 
2 03 
3 76 
1 80 
I 14 
3 00 
3 88 
3 23 
3 35 
6 76 
11 54 
2 49 
1 14 
11 54 
3 91 
3 23 
BVof 
IBD/ 
TBVIC 
% 
152 
-
-
-
125 5 
-
-
21 7 
0 6 
1 4 
-
-
125 5 
149 
-
MVof 
IBD/ 
MVIC 
% 
75 
-
-
-
41 8 
-
-
6 5 
0 1 
0 1 
-
-
41 8 
5 1 
-
LI M Return 
EBir 
% 
(42 7) 
(132 2) 
(314) 
(HO) 
(55 7) 
(2 2) 
(14 0) 
(28 5) 
(40 2) 
(79 4) 
(5 7) 
(132 2) 
(2 2) 
(40 3) 
(314) 
EBD1 T 
% 
(36 7) 
(124 3) 
(29 6) 
(100) 
(46 4) 
0 0 
(7 1) 
(16 8) 
(37 7) 
(75 1) 
(3 8) 
(124 3) 
0 0 
(35 2) 
(29 6) 
on TBVIC 
DFNI 
% 
(42 7) 
(132 2) 
(314) 
(110) 
(55 7) 
(2 2) 
(14 0) 
(28 5) 
(40 2) 
(79 4) 
(5 7) 
(132 2) 
(2 2) 
(40 3) 
(314) 
DrCF 
% 
(36 7) 
(124 3) 
(29 6) 
(100) 
(46 4) 
0 0 
(7 1) 
(16 8) 
(37 7) 
(75 I) 
(3 8) 
(124 3) 
0 0 
(35 2) 
(29 6) 
5-Year Average Return on TBVIC 
_ _ _ 
% 
(58 2) 
(50 2) 
(12 7) 
(5 5) 
(54 2) 
(16 1) 
1 5 
(25 6) 
(22 3) 
(48 8) 
(3 5) 
(58 2) 
1 5 
(26 9) 
(22 3) 
EBDir 
% 
(48 5) 
(45 7) 
(11 8) 
(4 9) 
(44 6) 
(14 5) 
7 9 
(172) 
(20 9) 
(45 3) 
(2 2) 
(48 5) 
79 
(22 5) 
(172) 
DFNI 
% 
(58 2) 
(50 2) 
(12 7) 
(5 5) 
(54 2) 
(16 1) 
07 
(25 6) 
(22 3) 
(48 8) 
(3 5) 
(58 2) 
07 
(27 0) 
(22 3) 
DI Cl: 
% 
(48 5) 
(45 7) 
(11 8) 
(4 9) 
(44 6) 
(14 3) 
7 1 
(172) 
(20 9) 
(45 3) 
(2 2) 
(48 5) 
7 1 
(22 6) 
(172) 
American Biomed Inc 
Angeion Corp 
Cardiogenesis Corp 
Cardiovascular Dynamics 
Llectro Catheter Corp 
Lndosonics Corp 
Luther Medical Products 
Mcdamicus Inc 
Perclose Inc 
Possis Medical Inc 
Rochester Medical 
LOW 
HIGH 
MEAN 
MfDIAN 
Zmetics Medical, Inc 22,151 1491 08 0 1 33 2 37 5 28 6 32 9 193 21 7 164 188 
Definitions, sources, and footnotes are found on the final page of Exhibit V 
EXHIBIT V 
ZINETICS MEDICAL, INC. 
MARKET APPROACH 
GUIDELINE PUBLICLY TRADED COMPANY METHOD 
DEFINITIONS, FOOTNOTES, AND SOURCES TO EXHIBITS 
Definitions* 
BV - Book value 
Df - Deficit 
TYE = Tiscal year-end 
IBD = Interest-bearing debt 
1C = Invested capital 
LTM = Latest 12 months 
MV = Market value 
MVIC = LTD + ST interest-bearing debt + MV of preferred + MV of common equity 
NA = Not available 
NM = Not meaningful 
T = Iangible 
I BV1C = Stockholders' equity - goodwill + LTD + ST interest-bearing debt 
Footnotes: 
[a] Book value if not publicly traded 
[b) Per most recently available data prior to the valuation date 
[c) Includes latest 12 months if at least six months beyond latest fiscal year-end 
[d] from earliest year on the table to the latest 12 months period 
Sources SCC Tortus 10-K and 10-Q, Annual Reports to Shareholders, Standard & Poor's Compustat and Dtalog-on-Disc, 
Disclosure's Compact Disclosure, and WMA Calculations 
EXHIBIT VI 
ZINETICS MEDICAL, INC. 
MARKET APPROACH 
GUIDELINE PUBLICLY TRADED COMPANY METHOD 
VALUATION SUMMARY 
Financial 
Fundamental 
Subject 
Company 
$000 
Low 
Industry Pricing Multiples 
High Mean Median Selected 
Indicated 
Value 
$000 
Emphasis 
Horizon 
% 
Multiple 
% 
Indicated 
Value 
$000 
Revenues 
Latest Twelve Months 
5-Year Average 
2,612 
1,833 
0 80 
0 69 
44 01 
99 20 
15 11 
27 80 
1036 
17 52 
10 00 
18 00 
26,120 
32,989 
70 0 
30 0 
100 0 28,181 | 
Market Value ol Invested Capital 
I ess Interest-bearing Debt 
Market Value of lolal Common Stock 
28,181 
|2_ 
28,168 
Source: Exhibit V 
EXHIBIT VII 
ZINETICS MEDICAL, INC. 
INCOME APPROACH 
DISCOUNTED CASH FLOW METHOD 
HISTORICAL AND PROJECTED INCOME STATEMENTS 
SCENARIO 1 
Total Revenues 
Annual Growth Rate (%) 
Cost of Sales 
Gross Profit 
LIM 
Lnding 
1/2/98 
$000 
12.612) 
1,035 
1,577 
v ' f ' 
Year 1 
$000 
4,153 
59% 
1,246 
2,907 
Projected Ye 
Year 2 
$000 
5,607 
35% 
1,682 
3,925 
Year 3 
$000 
6,728 
20% 
2,018 
4,710 
ars 
Year 4 
$000 
8,006 
19% 
2,402 
5,604 
Year 5 
$000 
9,608 
20% 
2,882 
6,725 
LIM 
Lnding 
1/2/98 
% 
100 0% 
39.6% 
60 4% 
Year 1 
% 
100 0% 
30.0% 
70 0% 
Pro|ecled Ye 
Year 2 Year 3 
% % 
100 0% 100 0% 
300% 30.0% 
70 0% 70 0% 
ars 
Year 4 
% 
100 0% 
30,0% 
70 0% 
Year 3 
% 
100 0% 
30.0% 
70 0% 
Administrative fxpenses [a] 
Net Income 
+ Interest I \pense 
+ Depreciation and Amortization Expense [b] 
- Capita! Lxpenditures (c) 
- Net Working Capital Requirements [d] 
+ NOL lax Carryforward [c) 
Net free Cash I low 
1,180 1,246 1,402 1,682 2,002 2,402 
397 1,661 2,523 3,028 3,603 4,323 
45 2% 30 0% 25 0% 25 0% 2:> 0% 25 0% 
15.2% 40.0% 45.0% 45 0% 45 0% 4S Q% 
1 
65 
NM 
NM 
NM 
1 
60 
(187) 
(308) 
1,107 
1 
111 
(104) 
(291) 
53 
1 
108 
(193) 
(224) 
-
1 
142 
(143) 
(256) 
-
1 
142 
(142) 
(320) 
-
2.334 2.292 2.719 3.347 4.004 
Sources Company audited and internally prepared (unaudited) financial statements and management projections 
[a) Net amount of all other income and expenses (e g operating expenses, interest income/expense, bad debt expense, income taxes) 
[b) Projected to be 40% oi prior year Net PP&C 
[c) Based on iixed asset turnover analysis and projected depreciation and amortization expense 
Id] Projected to be 20% of incremental revenues, based on historical ratios 
[el Projects a 40% elleetive income lax rate Total NOl tax carryforward as of the Valuation Dale was $2 9 million 
EXHIBIT VIII 
ZINETICS MEDICAL, INC. 
INCOME APPROACH 
DISCOUNTED CASH FLOW METHOD 
HISTORICAL AND PROJECTED INCOME STATEMENTS 
SCENARIO 2 
LTM 
fouling 
1/2/98 Year 1 
$000 $000 
Projected Years 
Year 2 
$000 
Year 3 
$000 
Year 4 Year 5 
$000 $000 
LTM 
Ending Projected Years 
1/2/98 Year 1 Year 2 Year 3 Year 4 Year 5 
% % % % % % 
Total Revenues 2,612 3,918 4,702 
Annual Growth Rate (%) 
Cost of Sales 
Gross Profit 
Administrative Expenses [a] 
Net Income 
+ Interest Expense 
+ Depreciation and Amortization Expense [b] 
- Capital Expenditures [cj 
- Net Working Capital Requirements [d] 
+ NOL fax Carry forward [e] 
5fi42 6,770 8.124 
50% 20% 20% 20% 20%" 
1,035 1,763 2,116 2,539 3,047 3,656 
100.0% 100.0% 100.0% 100.0% 100.0% 100 0% 
1,577 2,155 2,586 3,103 3,724 4,468 
1,180 1,371 1,646 1,975 2,370 2,844 
397 784 940 1,128 1,354 1,625 
1 
65 
NM 
NM 
NM 
1 
60 
(163) 
(26!) 
522 
1 
101 
(54) 
(157) 
627 
1 
82 
(195) 
(188) 
11 
1 
127 
(92) 
(226) 
-
1 
113 
(113) 
(271) 
-
39.6% 4S.Q% 45.0% 450% 45.0% 4S.0% 
60.4% 55.0% 55.0% 55.0% 55.0% 55.0% 
45.2% 35.0% 35.0% 35 0% 35 0% 35 0% 
15.2°/o 20.0% 20.0°/^ 20.0% ?0.0% ?0.0% 
Net'Free Cash Flow UU = 2 3 2 1,45$
 v3? 1.16? 1.35? 
Sources: Company audited and internally prepared (unaudited) financial statements and management projections. 
[a] Net amount of all other income and expenses (e.g. operating expenses, interest income/expense, bad debt expense, income taxes). 
[b] Projected to be 40% of prior year Net PP&E. 
[c] Based on Fixed asset turnover analysis and projected depreciation and amortization expense. 
[d] Projected to be 20% of incremental revenues, based on historical ratios. 
[e] Projects a 40% effective income tax rate. Total NOL tax carryforward as of the Valuation Date was $2.9 million. 
EXHIBIT IX 
ZINETICS MEDICAL, INC. 
INCOME APPROACH 
DISCOUNTED CASH FLOW METHOD 
HISTORICAL AND PROJECTED INCOME STATEMENTS 
SCENARIO 3 
i l M 
i ndmg 
1/2/98 Year 1 
$000 $000 
Projected Years 
Year 2 Year 3 Year 4 Year 5 
$000 $000 $000 $000 
MM 
1 ndmg Projected Years 
1/2/98 Year I Year 2 Year 3 Year 4 Year > 
% % % % % % 
Total Revenues 2,612 3,190 f K 5,741 
Annual Growth Rate (%) 
Cost of Sales 
Gross Prolit 
Administrative Expenses [a] 
Net Income 
+ Interest Expense 
+ Depreciation and Amortization Expense (b) 
- Capital Expenditures [c] 
- Net Working Capital Requirements [d] 
+ NOL 1 ax Carrylorward [e] 
I 
65 
NM 
NM 
NM 
22%,
 v80% 
1,035 1,435 
1,577 1,754 
1,180 1,116 
397 638 
I 
60 
(88) 
(116) 
425 
1,722 
4,019 
1,340 
2,679 
1 
71 
(275) 
(510) 
735 
6,890 8,268 
20% 
4,823 5,787 
1,608 1,929 
3,215 3,858 
1 
153 
1 
103 
(29) (321) 
(230) (276) 
9,921 
20%  20% 
2,067 2,480 2,976 
6,945 
2,315 
4,630 
1 
190 
(190) 
(331) 
100 0% 100 0% 100 0% 100 0% 100 0% 100 0% 
39.6% 45 0% 300% 30.0% 30 0% 30.0% 
60 4% 55 0% 70 0% 70 0% 70 0% 70 0% 
45 2% 35 0% 23 3% 23 3% 23 3% 23 3% 
15.2% 20.0'/, 467% A^J% 46.1% 46.7% 
Net Free Cash flow \M 920 2.700 3110 3.366 4.300 
Sources. Company audited and internally prepared (unaudited) financial statements and management projections 
[a] Net amount of all other income and expenses (e g operating expenses, interest income/expense, bad debt expense, income taxes) 
[bj Projected to be 40% ol prior year Net PP&E 
[c] Uased on fixed asset turnover analysis and projected depreciation and amortization expense 
[d] Projected to be 20% of incremental revenues, based on historical ratios 
[e] Projects a 40% eflective income tax rate Total NOL tax carryforward as of the Valaution Date was $2 9 million 
Note Year 1 Sales equal the sales total per the Annual Contract for Products for Medtronics/Synectics, effective 12/1/97 
This amount does not include 24E external, multi-use pH catheters, for which a quantity and price has not yet been determined 
Additionally, noncontractual sales to Medtronic/Synectics and sales to other customers are not included ^ 
Annual increases in sales and costs as a percentage of sales arc all estimated using the median percentage from Scenarios 1 - ^ lor each year 
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EXHIBIT X 
ZINETICS MEDICAL, INC. 
INCOME APPROACH 
DISCOUNTED CASH FLOW METHOD 
REQUIRED RETURiN ON EQUITY CAPITAL 
Cost of Equity Capital Source 
Risk-Free Rate of Return 
long-term Equity Risk Premium 
Industry Beta 
Beta-adjusted Equity Risk Premium 
Small Stock Equity Risk Premium 
Compan> Specific Equity Risk Premium 
Total Equity Rate 
7 8% 
1 07 
6 0% 
8 3% 
3 3% 
_____ 2 5% 
20 2% 
The Wall Street Journal February 16, 1998 
Stocks Bonds Bills <& Inflation 1998 Yearbook, Ibbotson Associates 
Cost of Capital Quarterly 1997 Yearbook Ibbotson Associates 
Stocks Bonds Bills & Inflation 1998 Yearbook, Ibbotson Associates 
Analysts' estimate 
Cost of Equity Capital (Rounded): 20% 
Sources: As indicated above 
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EXHIBIT XI 
ZINETICS MEDICAL, INC. 
INCOME APPROACH 
DISCOUNTED CASH FLOW METHOD 
VALUATION SYNTHESIS 
SCENARIOS I - 3 
Scenario 1: 
Net Cash Flow ($000) 
Present Value Factor @ 20 0% [a] 
Present Value (S000) 
X Direct Capitalization Multiple 
Terminal Value (S000) 
Present Value Factor @ 20 0% [b] 
Present Value of Terminal Cash Flow ($000) 
Scenario 2: 
Net Cash Flow ($000) 
Present Value Factor @ 20 0% [a] 
Present Value ($000) 
X Direct Capitalization Multiple 
Terminal Value ($000) 
Present Value Factor @ 20 0% [b] 
Present Value of Terminal Cash Flow 
Scenario 3: 
Net Cash Flow ($000) 
Present Value Factor @ 20% [a] 
Present Value ($000) 
X Direct Capitalization Multiple 
Terminal Value ($000) 
Present Value Factor @ 20% [b] 
($000) 
Present Value of Terminal Cash Flow ($000) 
Year I 
2,334 
0 9129 
2,130 
942 
09129 
860 
920 
0 9129 
840 
Year 2 
2,292 
0 7607 
1,744 
1,458 
0 7607 
1,109 
2,700 
0 7607 
2,054 
Year 3 
2,719 
0 6339 
1,723 
839 
0 6339 
532 
3,110 
0 6339 
1,971 
Year 4 
3,347 
0 5283 
1,768 
1,165 
0 5283 
615 
3,366 
0 5283 
1,778 
Year 5 
4,004 
_0_4402_ 
1,763 
1,355 
0 4402 
596 
4,300 
0 4402 
1,893 
Terminal 
Year [c] 
4,204 
6.67 
28,027 
0 4019 
11,263 
1,422 
6.67 
9,483 
0 4019 
3,811 
4,515 
6.67 
30,099 
04019 
12,096 
[a] Calculated based on mid-year present value discounting convention 
[b] Calculated based on year-end present vaJue discounting convention 
[c] Predicts a terminal value long-term expected growth rate of 5% 
Page I of 2 
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EXHIBIT XI 
ZINETICS MEDICAL, INC. 
INCOME APPROACH 
DISCOUNTED CASH FLOW METHOD 
VALUATION SYNTHESIS 
SCENARIOS 1 -3 
(in SOOOs, except per share data) 
PV of Discrete 
Cash Flows 
Scenario I: 
9,128 
Scenario 2: 
3,713 
Scenario 3: 
PV of Terminal 
Cash Flows 
11,263 
3,811 
Market Value ot 
Invested Capital 
20,392 
7,524 
Lons-term 
Interest-bearing 
Debt 
(12) 
(12) 
Market Value 
of Total 
Common StocK 
20,380 
7,512 
X 
X 
Value 
Indication 
Weighting 
25% 
25% 
Weighted 
Value 
Indication 
5,095 
1,878 
8,536 12,096 20,632 (12) 20,620 X 50% 10,310 
INDICATED FAIR VALUE OF EQUITY BASED ON WEIGHTED AVERAGE OF SCENARIOS I - 3: 17,283 
INDICATED PRICE PER SHARE BASED ON 128,806,800 SHARES OUTSTANDING: 0.134 
Page 2 of 2 
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EXHIBIT XII 
ZINETICS MEDICAL, INC. 
FAIR VALUE OF COMMON SHARES 
AS OF FEBRUARY 13, 1998 
Valuation 
Approach 
Market Approach 
Income Approach 
Valuation Method 
Guideline Publicly Traded Company Method 
Discounted Cash Flow Method 
Value 
Indication 
(Rounded) 
$ 28,168,000 
$ 17,283,000 
JFair \ alue of Total Common Stock 
Zinetics total common shares outstanding as of February 13, 1998 
[Fair Value of Common Stock per Share 
S 22,726,000 | 
128,806,800 
S 0.176 | 
APPENDIX B 
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SIGNIFICANT ECONOMIC FACTORS 
UNITED STATES 
• In the fall of 1997, there was a sharp depreciation in the currencies of many so-called emerging 
economies in Southeast Asia and Latin America. Turmoil in many of the Asian currency and equity 
markets continues, and local Asian politicians seem reluctant to undertake difficult but necessary 
economic, regulatory, and market reforms. 
• Asia's economic distress raises a question mark for economic growth in 1998 in the United States. 
Imported goods are expected to be less expensive for Americans, but shrinking exports may cause job 
losses in some industries that rely on sales in foreign markets. 
• The U.S. economy has been expanding since March 1991, generating millions of new jobs and rising 
incomes. In 1997, gross domestic product (GDP) gained 3.8 percent, the strongest growth since 1988. 
In the fourth quarter of 1997, GDP surged ahead at a 4.3 percent rate, well ahead of analysts' estimates. 
Inflation, on the other hand, virtually disappeared. Prices increased at the slowest rate since the mid-
1960s. Inflation increased by only 1.7 percent in 1997. Job creation and profit growths were strong. 
• GDP is expected to slow sharply in the first half of 1998 because of a falloff in exports to Asia and 
because of slower production as current high inventory levels are reduced. Approximately one-third of 
the nation's exports are to the Asia-Pacific Rim region and Japan. 
• The federal budget for fiscal 1998, that ends September 30, 1998, could contain a surplus, the first in 
many years. President Clinton will propose a balanced federal budget for fiscal 1999, three years ahead 
of schedule. 
• Federal Reserve Chairman Alan Greenspan reported to Congress that as the U.S. economy entered 
1998, it looked exceptionally healthy, benefiting from robust gains in output, employment, and income, 
with falling inflation. He indicated that Asia's economic crisis would give the U.S. economy some 
breathing space from inflationary pressures, although tight labor markets still pose risks. 
• The consumer price index (CPI) increased 0.1 percent in August 1997. For the year ending August 31, 
1997, the CPI increased 1.7 percent, the smallest yearly increase since 1986. Inflation drifted lower 
throughout 1997, but is expected to increase in 1998 and 1999, due to rising service sector prices and 
stabilization of goods prices. The CPI, minus the volatile food and energy components (called the 
"core" CPI), gained 2.2 percent in 1997, the smallest gain since 1965. Prices for services, which make 
up 60.0 percent of the CPI, increased 2.8 percent in 1997. 
• The U.S. index of import prices decrease 0.6 percent in August 1997. For the 12 months ending in 
August 1997, import prices declined 4.9 percent, the largest drop since the index was established in 
1982. 
• Nonfarm employment increased by 370,000 in August 1997. For all of 1997, employment expanded by 
an average of more than 267,000 jobs a month, or 2.7 percent, for a total of 3.2 million jobs added in 
1997. The unemployment rate for August 1997 was 4.7 percent. Unemployment in the last quarter of 
1997 was at the lowest point since the first quarter of 1970. 
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• The U S Department of Labor employment cost index (ECI) climbed 1 0 percent in the last quarter of 
1997—the sharpest gain since the last quarter of 1992. The wages and salaries component of the ECI 
grew 1 1 percent, the biggest gam in seven years. Benefit costs increased 0 9 percent, more than twice 
the rate of increase in the third quarter of 1997 For all of 1997, pay and benefits increased 3.3 percent, 
about double the rate of inflation for the year. 
• Consumer spending increased in the fourth quarter of 1997, after slowing m the third quarter. The 
outlook for the first part of 1998 is for healthy spending. In August 1997, consumer spending increased 
0.3 percent, and for all of 1997 consumer spending was ahead 5 4 percent. 
• Retail sales for the full year 1997 increased 4.2 percent, the slowest increase since 1991, when the last 
recession was ending Christmas sales were disappointing for many retailers. The value of retailers' 
sales increased at a 9.0 percent annual rate in August 1997. For the fourth quarter of 1997, however, 
retail sales grew only 1.0 percent after a 7.5 percent increase in the third quarter. 
• Personal income increased 0.4 percent in August 1997. For 1997, personal income gained 5.8 percent, 
slightly more than in 1996. 
• Consumer confidence was measured at 134.5 percent in August 1997, a 28-year high. Consumers 
clearly have high expectations for 1998. 
• Personal bankruptcies jumped 19.5 percent in 1997 to a record 1.34 million. The increase comes despite 
a booming economy with low unemployment. 
• Total construction spending in August 1997 increased slightly to an annual rate of $611.8 billion from 
November's rate. Total construction includes residential, commercial, and government projects. For all 
of 1997, construction spending gained 5.6 percent, compared to a 6.5 percent increase in 1996. 
• Pnvately owned housing starts were at a 1,519,000 annual rate in August 1997, a decrease of 0.8 
percent from November's rate. For the fourth quarter of 1997, however, housing starts averaged 
1,526,000 units—a 4.8 percent increase over the third quarter starts. Single-family starts declined 5.9 
percent in August, while apartment starts surged ahead 15.4 percent. 
• New home sales declined 9.7 percent in August 1997, the largest monthly drop in more than two years. 
New home sales for all of 1997 increased 5.7 percent. The number of homes sold in 1997 (800,000) was 
the highest since 1978. The inventory of new homes increased in August to a 4.6-month supply. 
• Sales of existing single-family homes in 1997 reached 4.21 million units, setting a new record despite a 
21 0 percent decline in August. The National Association of Realtors said the housing market was 
flooded with first-time and move-up buyers in 1997. In August 1997, there were 1.54 million homes 
available, representing a 4.3-month supply. The low supply suggests the market has tightened and could 
cause sharper price increases. 
• 1997 ended with stocks turning in a third year of very strong results. The Standard & Poor's 500 
increased 31.0 percent. The Dow Jones Industnal Average increased 22.6 percent in 1997. The index 
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gained 33.0 percent in 1995 and 26 0 percent m 1996 The Nasdaq composite gained 21 6 percent in 
1997 
• Industrial production slowed to a gain of 0 5 percent in August 1997, due in part to a 3 6 percent decline 
in output of motor vehicles. Industrial production for the fourth quarter of 1997, however, increased at a 
strong 7.4 annual rate For the entire year 1997, total production increased 5 9 percent. 
• 1997 was a strong year for manufacturing. Factory orders gained 5.3 percent, compared to a 4.6 percent 
increase in 1996. 
• In August 1997, durable goods orders decreased by 6.1 percent to $183.6 billion. Despite August's 
decline, durable goods orders increased 7.1 percent in 1997. In the fourth quarter of 1997, durable 
goods orders increased at an 8.2 percent annual rate, down from the 14.9 percent increase in the third 
quarter of the year. 
• Inventories of unsold goods swelled at an annual rate of $59.9 billion in 1997's last quarter, up from an 
annual rate of increase of $47 5 billion in the third quarter of the year. Companies will need to work 
their inventories down before ordering more goods, which could lead to a slowing of production. 
• The National Association of Purchasing Management's index was at 52.5 in August 1997, down 1.9 
percent from November's reading. It averaged 55.0 for 1997. A value of 50.0 or above indicates an 
expanding manufacturing sector. 
• The producer price index (PPI) for finished goods decreased 0.2 percent in August 1997. For the 12 
months ending August 1997, the PPI fell 1.3 percent, the first yearly drop since 1986. Prices of raw 
industrial commodities have declined by about 10.0 percent since the beginning of fall 1997. 
• Capacity utilization at the nation's factories was at 83.4 percent in August 1997. Capacity utilization at 
85.0 percent or above is considered by the Federal Reserve Board as a flash point for inflationary 
problems. Manufacturing capacity in the United States increased about 5.3 percent in 1997. 
• Companies cut back on plant and equipment investment in the fourth quarter of 1997 at a 3.6 percent 
rate. This was the first quarter in six years in which companies shrank their expansion plans rather than 
expanding them. Business spending on capital equipment is expected to remain strong in 1998. 
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DESCRIPTION OF THE GUIDELINE PUBLICLY TRADED COMPANIES 
T H E USE OF GUIDELINE PUBLICLY TRADED COMPANIES 
It has often been stated that all values are best tested and determined in the marketplace However, when 
valuing the shares of a privately held company, generally no such marketplace exists. Often the best 
alternative is to look for guidance from the prices investors are willing to pay for securities of similar 
companies that are publicly traded. 
The "willing buyer/willing seller" concept underlying the fair value concept comes from the concept that 
the buyer is seeking an equity participation in a particular industry, and that 'Value" to the buyer is a 
function of the strength and quality of earnings, assets, dividend yield, and/or some other relevant variable 
To gain valuation guidance from this approach, the first step is to identify a group of publicly traded 
companies that are sufficiently similar to Zinetics to classify them as guideline companies 
T H E SEARCH FOR GUIDELINE PUBLICLY TRADED COMPANIES 
The first step in finding guideline companies is to identify the most appropriate Standard Industrial 
Classification (SIC) code. The operations of Zinetics most closely resemble companies with SIC code 
3841—surgical and medical instruments and apparatus—in their business segment disclosures. We used the 
following on-line databases through Dialogue (database service) in the search for publicly traded 
companies: Disclosure and S&P Corporate Descriptions. 
Disclosure contains detailed financial and textual information on approximately 11,400 public companies 
The information is denved from documents filed with the Secunties and Exchange Commission (SEC) and 
is updated on a weekly basis. 
S&P Corporate Descriptions contains strategic and financial information on approximately 9,000 publicly 
owned corporations with secunties trading on the New York, Amencan and regional stock exchanges, 
NASDAQ system, and vanous exchanges in Canada and abroad. The file is updated with approximately 
400 revised and new records twice a month. 
We searched these databases by pnmary and secondary SIC codes. The pnmary SIC code is determined by 
identifying the predominant product or group of products produced or handled, or service rendered. The 
secondary SIC code is determined by identifying any product line which is not predominant but contributes 
to greater than 5 percent of the operational revenues of the company. 
A summary descnption of the business operations of each of the guideline publicly traded companies is 
provided below. 
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DESCRIPTION OF THE GUIDELINE COMPANIES 
American BioMed, Inc. 
American BioMed, Inc ("American BioMed"), including its wholly-owned subsidiaries, is a development 
stage enterprise, is engaged in the development, manufacture and marketing of medical devices. 
American BioMed primary technology is directed at interventional cardiology, endovascular surgery, and 
minimally invasive surgical devices The principal products are atherectomy catheters, stents, clot filters, 
100 percent silicone balloon catheters, and drug delivery catheter systems. The American BioMed primary 
business strategy is to design and develop minimally invasive medical devices to treat atherosclerotic 
disease. American BioMed holds patents on its OmniCath® atherectomy catheter, a device that 
mechanically removes the atherosclerotic disease ("plaque") from within blood vessels or other synthetic 
implanted vessel devices. American BioMed also has patent and/or proprietary rights to stent devices, the 
OmniStent™ and the OmniFilter, a catheter-mounted temporary blood filter. These devices are implantable 
within the vessel of the body to maintain an open lumen allowing necessary rates of blood flow. 
Angeion Corporation 
Angeion Corp ("Angeion") designs, develops, manufactures, and markets products that treat irregular 
heartbeats (arrhythmias). Angeion has developed the SENTINEL® series of implantable cardioverter 
defibrillators ("ICDs"), which it believes are among the smallest and most technologically advanced ICDs 
in clinical studies or market approved today. ICDs are designed to treat abnormally rapid heartbeats in the 
ventricular (or lower) chambers of the heart, conditions such as ventricular tachycardia ("VT'), and a severe 
form of VT known as ventricular fibrillation ("VF"), which if not terminated, will lead to sudden cardiac 
death ("SCD"). ICDs are electronic devices that are implanted within the body and are connected to the 
heart with defibrillator leads. These devices monitor the patient's heartbeat and, in the event of VT or VF, 
deliver an electrical shock to return the heartbeat to normal rhythm. 
Angeion is also developing a radio frequency ("RF") catheter ablation system that it believes offers a 
potential cure for certain forms of atrial arrhythmias (rapid heartbeats ongmating in the upper chambers of 
the heart) and a laser catheter ablation system that it believes offers a potential cure for certain forms of VT 
CardioGenesis Corporation 
CardioGenesis Corp. ("CardioGenesis") is developing proprietary probe and catheter systems to perform 
both surgical and catheter-based percutaneous transmyocardial revascularization ("TMR"). TMR is used to 
treat patients with severe coronary artery disease ("CAD") that suffer from recurrent debilitating chest pain. 
Unlike coronary angioplasty ("PTCA"), that are used to bypass, reopen, or widen blocked or narrowed 
arteries, TMR involves the use of laser energy, delivered through probes and catheters, to create typically 
between 15 and 30 channels in the oxygen-starved regions of the heart muscle. 
CardioGenesis is currently developing three TMR systems, based upon its patented technology, for use by 
cardiothoracid surgeons and interventional cardiologists to treat patients with severe CAD. 
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Cardiovascular Dynamics, Inc. 
Cardiovascular Dynamics, Inc ("CVD") designs, develops, manufactures, and markets catheters used to 
treat certain vascular diseases The CVD catheters are used in conjunction with angioplasty and other 
interventional procedures such as vascular stenting the drug delivery The CVD proprietary Focus and 
Multiple Microporous Membranbe technologies enable physicians to deliver therapeutic radial force, stents, 
drugs or contrast media accurately and effectively to the treatment site, and also allow the perfusion of 
blood during interventional procedure. 
CVD has utilized its core proprietary technologies to develop catheters that provide clinical and cost 
benefits in the treatment of vascular diseases CVD catheters are designed to address three principal 
challenges facing cardiologists* restenosis of a treated vessel, chronic total occlusions, and acute reclosure 
of a vessel during or soon after a procedure. 
Electro-Catheter Corporation 
Electro-Catheter Corp ("ECC") is engaged in the business of developing, manufacturing, and marketing 
products for hospitals and physicians. The majority of these products is utilized in connection with illnesses 
of the heart and circulatory system and makes use of catheters and related devices. ECC has targeted 
electrophysiology as its focal area for future growth, but intends to maintain and develop products for the 
emergency care, invasive and non-invasive cardiology, and invasive radiology markets. 
ECC produces a wide range of catheter products intended to be utilized by doctors and other trained hospital 
personnel for diagnostic and therapeutic purposes. They also produce catheters and hollow tubes that can be 
passed through veins, arteries, and other anatomical passageways. ECC considers the market within which 
it sells its present and proposed products as a single inductry segment. 
Endosonics Corporation 
Endosonics Corp ("Endosonics") develops, makes, and markets intravascular ultrasound imaging systems, 
catheters, balloon angioplasty catheters, stent delivery catheters, and site-specific drug delivery catheters 
which are used to assist in the diagnosis and treatment of cardiovascular and peripheral vascular disease. 
Endosonics develops, manufactures, and markets intravascular ultrasound (IVUS) imaging systems and 
catheters to assist in the diagnosis and treatment of cardiovascular and peripheral disease. 
The Endosonics IVUS imaging products enhance the effectiveness of the diagnosis and treatment of 
coronary artery and other vascular diseases by providing important diagnostic information not available 
from conventional x-ray angiography. This information includes the location, amount, and composition of 
atherosclerotic plaque and enables physicians to identify lesion charactenstics, select an optimum course of 
treatment, position therapeutic devices, and promptly assess the results of treatment. Endosonics 
angioplasty imaging catheters combine an angioplasty balloon and intravascular ultrasound imaging m a 
single catheter which may reduce the time and cost of interventional procedures by providing both 
diagnostic and therapeutic functions on the same catheter. 
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Luther Medical Products 
Luther Medical Products ("Luther") designs, develops, makes, sells, and licenses intra-vascular catheters 
and split, peel away needles used in short- and long-term intravenous therapy 
The Luther products include peripherally inserted central catheters, peripherally inserted midline catheters, 
peripherally inserted long-term peripheral catheters, the L-Cath peel-away needle catheter placement 
system, and the OneCath protected needle catheter placement systems which are used when soft, flexible 
catheters must be inserted for short- and long-term intravenous therapy In addition, Luther produces the L-
Cath for Port Access, which is a soft, flexible catheter utilized in the infusion of fluids into the blood stream 
through a small implanted chamber (a port) inserted under the skin of a patient's chest L-Cath for Ports 
offers an alternative to a steel Huber needle. 
Luther sells its products to original equipment manufacturers, hospitals, nursing homes, and home care 
markets in the U S and Canada, through approximately 21 distributors. 
MedAmicus, Inc. 
MedAmicus, Inc. ("MedAmicus") is a medical products company engaged in the design, development, 
manufacturing, and marketing of a pressure measurement system utilizing a propnetary fiber optic 
transducer for measuring and monitoring physiological pressures in the human body called the LuMax™ 
System. MedAmicus also manufactures and markets a percutaneous vessel introducer and the design and 
development of related vascular access products, as well as medical devices and components for other 
medical product companies on a contract basis. 
MedAmicus LuMax™ system consists of a monitor and catheter. The catheter contains optical fibers that 
transmit light in both directions within the catheter. The distal end of the catheter includes a stainless steel 
housing with an opening covered by a flexible membrane The membrane is designed to move into the light 
path in response to the pressure exerted. An external monitor emits the light and then measures the amount 
of light returned through the catheter for conversion into a pressure reading. In addition to reading pressure, 
the monitor calibrates the catheter, records pressures over time, and alerts the user to pressure readings 
outside of a specified range. 
Perclose Inc. 
Perclose Inc. ("Perclose") designs, develops, makes, and markets minimally invasive medical devices that 
automate the delivery of needles and sutures for the surgical closure or connection of blood vessels. 
Perclose is the technology leader in the development and commercialization of suture-based closure devices 
for artenal access site management, which are used following diagnostic and therapeutic catheter 
procedures 
The Perclose first family of products, the Prostar and Techstar products, surgically close artenal access sites 
(termed percutaneous vascular surgery or PVS) after cathetenzation procedures such as angioplasty, 
stenting, atherectomy, and angiography. Perclose is also developing devices that automate the connection of 
blood vessels in conventional and minimally invasive coronary artery bypass graft procedures. Perclose's 
propnetary Prostar, Prostar Plus, Prostar XL, Techstar, and Techstar XL products are designed to offer a 
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clinically superior and cost effective treatment alternative, providing the patient with the clinical benefits of 
rapid hemostasis, earlier ambulation, and improved patient comfort Perclose markets a full range of PVS 
closure products in the U S , Western Europe, Japan, and other Pacific Rim countries 
Perclose commenced international shipments of its Prostar and Techstar products in December 1994 and 
July 1995, respectively In 1997, Perclose received Food and Drug Administration (FDA) approvals for 
commercial sale in the U S. for the Prostar, Prostar Plus, Prostar XL, Techstar and Techstar XL products 
On January 5, 1998, Perclose announced that the FDA had granted approval of its Pre-Market Approval 
Supplement application for the Prostar Plus 8F, Prostar Plus 10F, and Prostar XL 8F PVS products for 
commercial sale in the U.S The Perclose Prostar Plus products have been used in Europe and Japan for 
over two years 
Possis Medical Inc. 
Possis Medical Inc ("Possis") develops, makes, and markets innovative medical products that assist 
surgeons and interventionists in treating cardiovascular or vascular diseases or conditions requiring vascular 
intervention. At July 31, 1997, the Possis products were in clinical tnals and in the early stages of 
commercialization Products included the Angiojet Rapid Thrombectomy System, the Perma-Flow Graft, 
and the Perma-Seal Graft. 
The Angiojet Rapid Thrombectomy System is a minimally invasive catheter system designed for rapidly 
removing blood clots with minimal vascular trauma. The Angiojet System removes the blood clots through 
the percutaneous insertion of the catheter over a guidwire into the patient's blood vessel and then, with the 
aid of fluoroscopy, the catheter is directed to the site of the blood clot. On December 6, 1996, Possis 
received FDA approval to commence U S. marketing of the Angiojet System with labeling claims for 
removal of blood clots from grafts used by patients on kidney dialysis. 
The Perma-Flow Graft is intended initially to provide a graft alternative to patients who require bypass 
surgery, but have insufficient or inadequate native vessels as a result of repeat procedures, trauma, disease 
or other factors. The Perma-Flow Graft is made of ePTFE, a standard graft material, and contains a molded 
silicone ventun-shaped flow resistance element approximately 2 millimeters in diameter As of September 
1997, 32 Phase 1 and 72 Phase 2 study patients were enrolled in 16 states 
The Perma-Seal Graft is a self-sealing synthetic graft compnsed of silicone elastomers, with a winding of 
polyester yarn encapsulated within its wall, and is manufactured using proprietary electrostatic spinning 
technology developed by Possis. 
Rochester Medical Corporation 
ochester Medical Corporation ("Rochester") makes and sells a broad line of functionally and 
technologically enhanced latex-free versions of standard continence care products, including male external 
catheters, Foley catheters, and intermittent catheters. 
Rochester, which makes continence care products, announced on January 14, 1998, that its new Nitrofiiran 
Delivery Catheter had received FDA clearance for marketing and sale. This new patented Foley type 
medicating catheter system delivers a sustained-release regimen of the active ingredient Nitrofurazone 
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directly into the urethral tract and bladder neck during the time the patient is cathetenzed Nitrofurazone is a 
recognized anti-infectant. 
Rochester makes and sells a broad line of functionally and technologically enhanced latex-free versions of 
standard continence care products, including male external catheters, Foley catheters and intermittent 
catheters Rochester is also developing innovative and technologically advanced products designed to 
provide clinically and commercially attractive solutions to continence care needs. 
Rochester has developed proprietary processes for the manufacture of silicone based disposable medical 
catheters. Products include a self-adhenng male external catheter for males who are incontinent, and 
internal catheters, known as Foley catheters, for men and women whose bladders require mechanical 
assistance to be drained. Rochester generally sells its products under pnvate label to distnbutors and other 
manufacturers of medical products. 
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INCOME APPROACH—SIGNIFICANT VALUATION VARIABLES 
SCENARIOS 
Dunng December 1996, Mr Steve Davis, Zmetics President, prepared several projections of the Zmetics 
operations For the purpose of our discounted cash flow (DCF) analysis, we incorporated two of Mr Davis' 
projected income statements as Scenarios 1 and 2. We also created a third scenario for our DCF analysis, 
based primarily on information provided by the deposition of Steve Davis on May 12, 1998, as well from 
Mr. Davis' aforementioned projections. 
These scenarios are presented on Exhibits VTI through D< Pertinent valuation variable and projections used 
in preparing these scenarios are noted on these exhibits 
Weightings 
For each of our three scenarios, we estimated the fair value of the Zmetics total common stock as of the 
Valuation Date We then emphasized each scenario based on the perceived likelihood of its occurrence. 
Scenarios 1 and 2 were each given a 25 percent weight and Scenario 3 was given a 50 percent weight. 
Greater emphasis was placed on Scenano 3 because it is based primarily on an actual sales contract as well 
as the deposition of Steve Davis. 
The valuation synthesis for these three DCF scenanos is presented on Exhibit XI. 
Effective Income Tax Rate 
We estimated that a combined effective federal and state income tax rate of 40 percent was appropriate for 
use in our valuation analyses. This income tax rate was applied in all three scenanos, as discussed above. 
PRESENT VALUE DISCOUNT R A T E 
We estimated that the required rate of return on equity capital was the appropriate present value discount 
rate to use in our valuation of Zmetics. The required rate of return on equity capital estimates the required 
rate of return on the Zmetics common stock, as determined by the market. 
Rate of Return on Equity 
In developing the required rate of return on equity capital, we used evidence presented in Stocks, Bonds, 
Bills and Inflation, Ibbotson Associates, 1998 According to the Ibbotson study, the average premium over 
the risk-free rate (as measured by 20-year Treasury bonds) for an equity investment in the S&P 500 
Composite Common Stock Index was 7.8 percent for the period 1926-1997. We multiplied this risk 
premium by an industry beta of 1 07, per Cost of Capital Quarterly, Ibbotson Associates, 1997, to estimate 
the beta-adjusted equity risk premium of 8.3 percent. We used this historical equity risk premium of 8 3 
percent as an estimate of the required market risk premium on equity capital. 
The equity risk premium was denved from a broad composite of returns of large, highly capitalized 
companies trading on the national exchanges. It does not take into account the business and financial risk, or 
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lack thereof, specific to the subject company's business activity and capital structure, nor does it incorporate 
the generally greater investment risk and resultant higher required rates of return normally associated with 
smaller, more thinly capitalized companies like Zinetics According to Ibbotson Associates Stocks, Bonds, 
Bills, and Inflation 1998 Yearbook, the mean return for stocks of small market capitalization companies 
over the period 1926 to 1997 reflected an additional small-stock risk premium of 3 3 percent over the 
generic risk premium found for the larger S&P 500 Composite Common Stock Index 
We selected a risk-free rate based upon the rate of return on 20-year U S Treasury bonds quoted in The 
Wall Street Journal as of the Valuation Date We selected 6 0 percent as our risk-free rate of return 
Zinetics faces certain unsystematic, or company-specific, risks that are not considered in the rates discussed 
above These risks include, but are not limited to, dependence on key personnel, changing international 
catheter markets, new product development, and possibly, limited financial resources Additionally, Zinetics 
is much smaller than the publicly traded companies used to measure the small stock risk premium We, 
therefore, concluded it appropnate to include an additional risk premium of 2 5 percent to reflect these 
idiosyncratic risks 
Based on our analysis of the nsk-free rate, the market equity risk premium, the small stock equity risk 
premium, and the unsystematic risks facing the Company, we calculated the required rate of return on 
equity capital for Zinetics at (rounded) 20 percent. 
A summary of our required rate of return on equity capital analysis is provided on Exhibit X. 
LONG TERM EXPECTED GROWTH RATE 
Based on (1) our analysis of the Zinetics financial statements for the years ended August 31, 1993 through 
August 31, 1997, as well as the latest twelve month period ended January 2, 1998, (2) discussions with 
management, and (3) the historical growth rate in revenues of our guideline publicly-traded companies, we 
have estimated a long-term expected growth rate of 5 percent for our residual value analysis. This growth 
rate is applied in all three scenarios, as discussed above 
We consider this long-term growth rate appropnate based upon (1) industry trends, (2) Zinetics position in 
the catheter market, (3) general inflation rates, and (4) increases in gross domestic product 
DIRECT CAPITALIZATION RATE 
The perpetuity direct capitalization ate used to estimate the residual value is calculated by subtracting the 
expected long-term growth rate from the estimated cost of equity capital. 
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This appraisal is made subject to the following general contingent and limiting conditions 
1 We assume no responsibility for the legal description or matters including legal or title 
considerations Title to the subject business interest is assumed to be good and marketable unless 
otherwise stated 
2 The subject business interest is appraised free and clear of any or all hens or encumbrances unless 
otherwise stated. 
3 We assume responsible ownership and competent management with respect to the subject business 
interest. 
4 The information furnished by others is believed to be reliable However, we issue no warranty or 
other form of assurance regarding its accuracy. 
5. We assume no hidden or unapparent conditions regarding the subject business interest. 
6. We assume that there is full compliance with all applicable federal, state, and local regulations and 
laws unless the lack of compliance is stated, defined, and considered m the appraisal report. 
7 We assume that all required licenses, certificates of occupancy, consents, or legislative or 
administrative authority from any local, state, or national government, or private entity or 
organization have been or can be obtained or reviewed for any use on which the opinion contained 
in this report is based. 
8. Unless otherwise stated in this report, we did not observe, and we have no knowledge of, the 
existence of hazardous materials with regard to the subject business interest. However, we are not 
qualified to detect such substances. We assume no responsibility for such conditions or for any 
expertise required to discover them. 
9. Possession of this report does not carry with it the nght of publication. It may not be used for any 
purpose by any person other than the client to whom it is addressed without our written consent, 
and, in any event, only with proper written qualifications and only in its entirety. 
10 We by reason of this opinion, are not required to furnish a complete valuation report, or to give 
testimony, or to be in attendance m court with reference to the business interest in question unless 
arrangements have been previously made. 
11. Neither all nor any part of the contents of this report shall be disseminated to the public through 
advertising, public relations, news, sales, or other media without our prior written consent and 
approval. 
12. The analyses, opinions, and conclusions presented in this report apply to this engagement only and 
may not be used out of the context presented herein. This report is valid only for the effective date 
specified herein and only for the purpose specified herein. 
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APPRAISAL CERTIFICATION 
We hereby certify the following statements regarding this appraisal 
1 We have no present or prospective future interest in the business interest that is the subject of this 
appraisal report 
2 We have no personal interest or bias with respect to the subject matter of this report or the parties 
involved 
3 Our compensation for making the appraisal is in no way contingent upon the value reported or upon 
any predetermined value 
4 To the best of our knowledge and belief, the statements of facts contained in this report, upon which 
the analyses, conclusions, and opinions expressed herein are based, are true and correct 
5 We have not personally inspected the business interests encompassed by this appraisal 
6 Our analyses, opinions, and conclusions were developed, and this report has been prepared, in 
conformity with the Uniform Standards of Professional Appraisal Practice, as promulgated by The 
Appraisal Foundation 
7 No persons other than the individuals whose qualifications are included herein have provided 
significant professional assistance regarding the analyses, opinions, and conclusions set forth in this 
report. 
8 The reported analyses, opinions, and conclusions are limited only by the reported contingent and 
limiting conditions, and they represent our unbiased professional analyses, opinions, and 
conclusions 
9 The reported analyses, opinions, and conclusions were developed, and this report has been 
prepared, in conformity with the requirements of the Code of Professional Ethics and the Standards 
of Professional Appraisal Practice of the Appraisal Institute, of the American Society of Appraisers, 
and of the other professional organizations of which we are members 
10 Disclosure of the contents of this report is subject to the requirements of the Appraisal Institute, the 
American Society of Appraisers, and the other professional organizations of which we are members 
related to review by their duly authorized representatives 
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ROBERT F. REILLY, CPA, CFA, ASA 
Robert Reilly is our firm's managing director for professional services These professional services include 
valuation consulting, economic analysis, and financial advisory services 
With regard to valuation consulting, Mr Reilly routinely serves clients in the following appraisal 
disciplines business valuation and security analysis, intangible asset and intellectual property appraisal, real 
estate and real property interest appraisal, and tangible personal property appraisal 
Mr Reilly has performed the following types of valuation and economic analyses event analyses, merger 
and acquisition appraisals, divestiture and spin-off appraisals, solvency analysis, fairness opinions, ESOP 
feasibility and formation analysis, post-acquisition purchase price allocation appraisals, business and stock 
valuations, real estate valuations and evaluations, tangible personal property appraisals, real estate 
feasibility and investment analyses, ad valorem assessment appeal appraisals, construction cost segregation 
appraisals, insurance appraisals, restructuring and workout appraisals, litigation support appraisals, and 
tangible and intangible asset transfer pricing analyses 
These valuation and economic analyses have been performed for the following purposes transaction pricing 
and structuring (merger, acquisition, liquidation, and divestiture), taxation planning and compliance (federal 
income, gift, and estate tax, and state and local property tax), financing securitization and collaterahzation, 
employee corporate ownership, litigation support and dispute resolution, strategic information and planning, 
insolvency and troubled debt workout analysis (recapitalization, restructuring), and fiduciary advice and 
financial counseling. 
Mr Reilly has appraised the following types of business entities and securities: close corporations—entity 
value, close corporations—fractional interests, public corporations—restncted stock, portfolios of 
marketable and nonmarketable securities, complex capital structures (various classes of common equity, 
preferred equity, and warrants, grants, nghts), general and limited partnership interests, joint ventures, 
propnetorships, professional service corporations, professional practices, license agreements, franchises, 
and intercompany transfer pncing agreements. 
He has performed economic analyses, valuation analyses, and remaining useful life analyses, and/or has 
estimated the appropnate transfer pnce on the following types of intangible assets and intellectual 
properties: advertising campaigns and programs, appraisal plant, bank customers, broadcast licenses, 
building permits, cable franchise ordinances, certificates of need, computer software, computer databases, 
core depositors, copynghts, credit information files, customer and supplier contracts, customer lists, 
distribution nghts, distnbution systems, employment contracts, engineenng drawings, film libranes, 
franchise contracts and nghts, going-concern value, goodwill, leasehold interests, licenses, literary 
compositions, loan portfolios, management contracts, manuscnpts, medical charts and records, mortgage 
servicing nghts, musical compositions, noncompete covenants, patent applications, patents, patient files and 
records, permits, possessory interests, pnzes and awards, procedural manuals, production backlogs, 
propnetary technology, solicitation nghts, subscnber lists, technical libranes, trained and assembled 
workforces, trade names, trademarks, training manuals and documentation, unpatented technology, and use 
rights—air, water, and land 
Mr Reilly has performed pre-acquisition and post-acquisition business and asset appraisals in the following 
industnes: accounting and consulting, advertising, apparel, appraisal, automobile dealerships, automobile 
manufacturing, aviation, bottling, brokerage, cable television, cement, chemical, commercial banking, 
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communications, computer services, construction and contracting, consumer finance, cosmetics, data 
processing, decontamination, distribution, education, entertainment, equipment leasing, fast food, food 
service, forest products, health care, hotel and hospitality, insurance, investment banking, leasing, 
manufacturing, medical and dental practice, mining and mineral extraction, money management, natural 
resources, petrochemical, pharmaceuticals, plastics, printing, public utilities, publishing, radio broadcasting, 
railroads, real estate development, recreational services, restaurant, retailing, shipping, steel, television 
broadcasting, textiles, thrift institutions, transportation and trucking, vocational training, and wholesaling. 
He has prepared numerous financial advisory analyses and economic analyses for merger and acquisition 
purposes. These analyses include: identification of merger and acquisition targets, appraisal of synergistic 
and strategic benefits of targets, identification and assessment of divestiture and spin-off opportunities, 
economic analysis of alternative deal structures, negotiation and consummation of deals, assessment of the 
fairness of proposed transactions, analysis of initial public offering (IPO) alternative pricing strategies, and 
design and valuation of alternative equity and debt instruments within a multitude investor environment. 
He has prepared valuation engineering, value enhancement, and owner wealth maximization analyses. 
Valuation engineering involves the development and implementation of tactics and strategies designed to 
maximize the value of assets, properties, and business interests. Mr. Reilly routinely performs valuation 
engineering analyses for owners of close corporations and for owners of income producing real property. 
These valuation engineering analyses are performed for transaction pricing, intergenerational wealth 
transfer, and management information purposes. 
Mr. Reilly conducts engineering depreciation, technological obsolescence and economic obsolescence 
studies for purposes of ad valorem property tax assessment appeal. These appraisals typically encompass 
the quantification of physical detenoration and functional, technological, and economic obsolescence of 
both real and personal property. These appraisals generally involve technology life cycle analyses and 
economic/product life cycle analyses. 
Mr Reilly has performed real estate appraisals and feasibihty/development/investment analyses of the 
following types of properties: commercial office buildings, easements, facades, hospitals, hotels, industrial 
cooperatives, industrial and manufacturing facilities, industrial parks, land improvements and 
infrastructures, mines, nursing homes, quarries, railroads, regional shopping malls, residential apartment 
complexes, restaurants, retail stores, strip shopping malls, timber land, vacant rural kind, vacant urban land, 
and warehouses. These appraisals have encompassed the following real estate interests: fee simple, 
leasehold interest, leasehold estate, possessory interests, life interests, reversionary interest, air rights, water 
rights, mineral rights, use rights and development rights. These appraisals have concluded the following 
standards of value: market value, fair value, insurable value, use value, collateral value, investment value, 
and ad valorem value. 
He has appraised the following types of tangible personal property* manufacturing machinery and 
equipment, processing machinery and equipment, mining and extractive equipment, construction 
equipment, data processing and office automation equipment, communications and telecommunications 
equipment, broadcasting equipment, office furniture and fixtures, vehicles and transportation equipment, 
aircraft, and laboratory and scientific equipment. 
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Mr. Reilly has been accepted as an expert witness on over 100 occasions in various federal, state, and 
international courts and before various state boards of equalization and tribunals. These litigation support 
services have related to business, stock, and asset appraisal matters and to economic damages matters. As 
an appraiser and economist, he has been an expert witness in the following types of litigation: bankruptcy, 
breach of contract, condemnation, conservatorship, corporate dissolution, expropriation, federal income tax, 
gift and estate tax, infringement (value of intangible assets), marital dissolution, minority shareholder rights, 
property tax appeal, reasonableness of executive compensation, solvency and insolvency, stockholder suits, 
tortious damages, and reasonableness of royalty rates and/or transfer prices. 
He has served as a court-appointed arbitrator with respect to minority squeeze-out merger shareholder rights 
actions. 
PREVIOUS EXPERIENCE 
Prior to Willamette Management Associates, Robert Reilly was a partner and national director of the 
Deloitte & Touche Valuation Group, the valuation and appraisal practice of the Big Six accounting and 
consulting firm. At Deloitte & Touche, Mr. Reilly authored the Valuation Group Practice Policy Manual 
and the Valuation Group Report Writing and Editorial Policy Manual. In addition, he was chairman of the 
practice's policymaking professional practices committees for business and stock valuation matters and for 
litigation support and dispute resolution matters. 
Prior to founding the Deloitte & Touche Valuation Group, Robert Reilly was vice president of Arthur D. 
Little Valuation, Inc., a national appraisal firm. He was also chairman of the firm's policymaking 
professional practices committee for financial valuation matters. 
Prior to that, Mr. Reilly was associated with Huffy Corporation, a diversified manufacturing firm. As 
director of corporate development, he was responsible for strategic planning and acquisition/divestiture 
analyses. As internal audit director, he was responsible for financial, operational, and EDP audit activities. 
As corporate tax manager, he was responsible for all tax research, planning, and compliance. As financial 
analyst, he was responsible for financial and operational planning. 
Prior to that, he was a senior consultant for Booz, Allen & Hamilton, an international management 
consulting firm. He consulted in the areas of financial analysis, planning, and control for clients in the 
transportation industry. 
EDUCATION 
Master of Business Administration, Finance, Columbia University Graduate School of Business 
Bachelor of Arts, Economics, Columbia University 
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PROFESSIONAL AFFILIATIONS 
Certified Public Accountant (Ohio and Illinois) 
Certified Management Accountant 
Certified Manufacturing Engineer 
Enrolled Agent (licensed to practice before the ERS) 
Accredited Tax Advisor (ATA)—Accreditation Council for Accountancy & Taxation 
Accredited Senior Appraiser (ASA)—American Society of Appraisers, in business valuation 
Certified Real Estate Appraiser (CREA)—National Association of Real Estate Appraisers 
Chartered Financial Analyst (CFA)—Association of Investment Management and Research 
Certified Review Appraiser (CRA)—National Association of Review Appraisers and Mortgage 
Underwriters 
From 1987 through 1989, Mr Reilly served as an examiner for the Board of Examiners—the examination 
and certification division—of the American Society of Appraisers, the national standards setting and 
certification organization in the appraisal industry 
Mr Reilly is a member of the American Bankruptcy Institute, American Economic Association, American 
Institute of Certified Public Accountants, American Society of Appraisers, Business Valuation Association, 
The ESOP Association, Illinois Society of Certified Public Accountants, Institute of Chartered Financial 
Analysts, Institute of Property Taxation, Institute of Management Accountants, National Association of 
Business Economists, National Association of Real Estate Appraisers, Ohio Society of Certified Public 
Accountants, and Society of Manufacturing Engineers. 
Mr Reilly is a state certified general real estate appraiser in the states of Illinois, Virginia, Utah, and 
Oregon 
He has completed the following real estate appraisal courses offered by the Appraisal Institute 110— 
appraisal principles, 120—appraisal procedures, 210—residential case study, 310—basic income 
capitalization, 320—general applications, 410—standards of professional practice A, 420—standards of 
professional appraisal practice B, 510—advanced income capitalization, 520—highest and best use 
analysis, 530—advanced cost and sales comparison approaches, 540—report writing and valuation analysis, 
and 550—advanced applications 
He is a state certified affiliate of the Appraisal Institute 
